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Abstract  17 
Background: Resistance against antibiotics is unfortunately still a major biomedical 18 
challenge for a wide range of pathogens responsible for potentially fatal diseases. 19 
Scope of Review: In this study, we aim at providing a critical assessment of the recent 20 
advances in design and use of drugs targeting genome integrity by perturbation of thymidylate 21 
biosynthesis. 22 
Major Conclusion: We find that research efforts from several independent laboratories 23 
resulted in chemically highly distinct classes of inhibitors of key enzymes within the routes of 24 
thymidylate biosynthesis. The present article covers numerous studies describing perturbation 25 
of this metabolic pathway in some of the most challenging pathogens like Mycobacterium 26 
tuberculosis, Plasmodium falciparum, and Staphylococcus aureus. 27 
General Significance: Our comparative analysis allows a thorough summary of the current 28 
approaches to target thymidylate biosynthesis enzymes and also include an outlook suggesting 29 
novel ways of inhibitory strategies.  30 
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Highlights 31 
 critical assessment of approaches against enzymes in thymidylate biosynthesis 32 
 detailed assessment of perturbation strategies to inhibit various families of dUTPases, 33 
thymidylate synthases and dihydrofolate reductases 34 
 focus on the biomedically most challenging pathogens 35 
 identification of novel strategies by e.g. proteinaceous inhibition 36 
 37 
 38 
 39 
 40 
Abbreviations 41 
CH2THF: 5,10-methylene tetrahydrofolate, DCD: dCTP deaminase, DCD-DUT:bifunctional 42 
dCTP deaminase – dUTPase, DUT: dUTPase, DHF: dihydrofolate, DHFR: dihydrofolate 43 
reductase, DHFR-TS bifunctional dihydrofolate reductase – thymidylate synthase, FAD: 44 
flavin adenine dinucleotide, SHMT: serine hydroxymethyltransferase, THF: tetrahydrofolate, 45 
TK: thymidine kinase, TS, ThyX: classical and flavin-dependent thymidylate synthase, 46 
TMPK: dTMP kinase, Ugi: uracil-DNA glycosylase inhibitor, UNG: uracil-DNA 47 
N-glycosylase. Abbreviations of organisms are listed in Table 1.  48 
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Background 49 
Despite huge efforts in antimicrobial drug design, numerous microbes still present excessive 50 
biomedical challenge all around the world, in less developed and highly developed countries 51 
alike. Major reasons for this unfortunate situation include several factors. Among these, high 52 
mutation rate in many pathogenic organisms that may be an inherent characteristic of bacterial 53 
species (e.g. presence of error-prone polymerases in Mycobacterium tuberculosis may lead to 54 
resistant strains [1]). Also, the over-excessive use of antibiotics drives the development of 55 
resistance. In this respect it is important to note that overuse of antibiotics in animal 56 
agriculture is a major hazard especially since these are frequently the very same chemical 57 
compounds that are used in human medicine. Antibiotics in the livestock and poultry feed 58 
presents a low-level exposure over long periods of time that strongly contribute to the 59 
appearance of resistant microbial strains. Wide availability of antibiotics is also a concern. 60 
Although in some countries, there is an increasingly cautious attitude towards prescribing 61 
antibiotics in minor illnesses, still, in many situations, prescriptions are easy to obtain for 62 
larger amounts of antibiotics, sometimes even as over-the-counter-drugs, as well. In addition 63 
to all these, patients carrying pathogenic microbes may easily spread the infection among 64 
different populations as traveling is largely facilitated via flights and other means of transport. 65 
The most efficient way to overcome the problems of microbial resistance against drugs is to 66 
focus on new pathways, to discover novel molecular targets such that the strains that became 67 
resistant against the “old” drugs could not rely on the already developed resistance 68 
mechanism. Despite the general agreement in these questions, the number of novel antibiotics 69 
with a new molecular mechanism of action developed over the last decades is very low. This 70 
is perhaps at least partially, but maybe mostly, due to the fact that the development of 71 
antibiotics is not among the most profitable actions for a drug company. Development of new 72 
drugs is a very complex and costly project, with inherent problems relating to unexpected 73 
side-effects when a pathway or protein is targeted that has not been previously among those 74 
affected by drugs in clinical use. Approval of novel drugs is also a lengthy and expensive 75 
process. These factors are deterrent for large pharmaceutical companies and contribute to the 76 
present suboptimal situation. 77 
No matter how few truly novel antimicrobial drugs have been introduced in the clinical use 78 
during the last years, the basic research background is much flourishing. Even a quick and 79 
superficial view on the number and variety of studies published in this context strongly argues 80 
Author manuscript published in: BBA - General Subjects 
5 
for the high momentum in the academic research on these fields. The present study attempts 81 
to cover most of the recent developments, focusing on investigations related to inhibition of 82 
enzymes involved in thymidylate biosynthesis as a novel target in multiple pathogenic 83 
microorganisms (Table 1). 84 
Genome integrity and thymidylate biosynthesis – why it is a promising field 85 
for novel drug candidates? 86 
For an effective drug candidate, the target protein has to be essential for the given organism. 87 
Microbe-specific enzymes are traditionally considered to be the best targets, however, in 88 
many instances, enzymes where homologues are also present in the host organism still may be 89 
good targets for design of antimicrobial diseases. Hence, the wealth of information gained on 90 
more complex eukaryotic systems, e.g. in cancer research may also be used in the research 91 
against infectious microbes. The common denominator in these issues may be found when we 92 
focus on the joint characteristics of infectious microbes and cancer cells – namely, during 93 
acute phases of the disease, these cells are all multiplying very fastly and drugs interfere with 94 
this increased division cycle. In the present study, we focus on thymidylate biosynthesis that 95 
is part of the preventive DNA repair pathways and responsible for maintaining genome 96 
integrity (Figure 1). Perturbation of this metabolic pathway was proven to be an important 97 
pharmaceutical strategy for both cancer and microbial cells. 98 
Thymidylate biosynthesis shows several characteristics different from the biosynthesis of 99 
other nucleic acid building blocks (Figure 1). Most importantly, the de novo biosynthesis of 100 
the thymine base is realized at the monophosphate nucleotide level from dUMP, provided 101 
mostly by the dUTPase enzyme, through the catalytic action of thymidylate synthases (TS or 102 
ThyX). The methyl group transfer to the 5’-position in the pyrimidine ring requires complex 103 
biochemical catalysis. Thymine containing nucleotides can also be regained by salvage 104 
pathways through thymidine kinase. The rather limited and constrained routes in thymidylate 105 
biosynthesis, together with its essentiality for DNA biosynthesis designates the enzymes 106 
within these pathways as key targets for development of antimicrobial drugs, while the human 107 
homologues of these enzymes are also very important entities in anticancer chemotherapy. 108 
Nevertheless both thymidylate synthase and dihydrofolate reductase enzymes are heavily 109 
studied primary enzymatic targets of antibacterial/antiparasite therapy [2,3]. However, there 110 
are other important drug targets amongst the folate pathway enzymes, for example 111 
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dihydropteroate synthase. Due to the indirect connection of these enzymes to dTTP 112 
biogenesis, detailed presentation of these are out of the scope of this review.  113 
Below, we will summarize in a comparative manner the current advances in application of 114 
enzymes involved in thymidylate biosynthesis as drug targets in several pathogens that still 115 
present major biomedical challenge (Table 1). 116 
  117 
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Table 1 List of organisms and their human relevance included in this study 118 
Organism (Abbreviation) Human relevance Section 
Bacillus anthracis (Ba) etiologic agent of anthrax DHFR, TMPK 
Campylobacter jejuni (Cj) gastric pathogen DUT 
Candida glabrata (Cg) 
Candida albicans (Ca) 
systemic infection agent DHFR 
Cryptococcus neoformans 
causative of fungal meningitis and 
encephalitis 
TS 
Cryptosporidium hominis, (Ch) 
Cryptosporidium parvum (Cp) 
gastric pathogen DHFR-TS, TK 
Enterococcus faecalis (Ef) 
causative of urinary tract infections and 
endocarditis 
TS, DHFR 
Helicobacter pylori (Hp) gastric pathogen ThyX 
Klebsiella pneumoniae (Kp) 
causative of urinary and respiratory  
tract infections 
DHFR 
Lactobacillus casei (Lc) LcTS is a model protein of classical TSs TS 
Leishmania donovani (Ld) 
causative of visceral leishmaniasis  
(black fever) 
DHFR-TS 
Leishmania major (Lm) causative of cutaneous leishmaniasis  
DUT, DHFR-TS, 
TK 
Mycobacterium tuberculosis (Mt) causative of tuberculosis 
DUT, DHFR 
ThyX, 
SHMT,TMPK Paramecium bursaria chlorella 
virus-1 (PBCV) 
PBCV-ThyX is a model protein of ThyX ThyX 
Plasmodium falciparum (Pf) 
Plasmodium vivax (Pv) 
Plasmodium ovale (Po) 
causatives of malaria DUT, DHFR-TS 
Pneumocystis carinii (Pc) 
Pneumocystis jirovecii (Pj) 
causatives of Pneumocystis pneumonia TS, DHFR 
Pseudomonas aeruginosa (Pa) 
causative of urinary tract and 
blood infections 
TMPK 
Staphylococcus aureus(Sa) 
causative of skin and respiratory 
infections 
TS, DHFR, TMPK 
Staphylococcus epidermidis (Se) 
causative agent of endocarditis,  
infects medical catheters and prostheses  
TS 
Streptococcus mutans (Sm) major aetiological agent of dental caries DHFR 
Toxoplasma gondii (Tg) causative of toxoplasmosis DHFR-TS 
Trypanosoma brucei (Tb) 
causative of African sleeping sickness 
(African trypanosomiasis) 
DUT, DHFR-TS, 
TK 
Trypanosoma cruzi (Tc) 
causative of Chagas disease  
(American trypanosomiasis) 
DUT, DHFR-TS, 
SHMT 
  119 
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Figure 1. Summary of the key steps in pyrimidine biosynthesis. Enzymatic reactions that 121 
are not ubiquitous are represented by dotted lines. Traditional antiparasitic drug target 122 
enzymes of the thymidylate biosynthesis are shown with white lettering on blue background, 123 
recently verified target enzymes are denoted with blue lettering. Abbreviations are as follows: 124 
CDA: cytidine deaminase, CH2THF: 5,10-methylene tetrahydrofolate, DCD: dCTP 125 
deaminase, DCD-DUT:bifunctional dCTP deaminase – dUTPase, DCDT: dCMP deaminase, 126 
dCTPP1: dCTP pyrophosphatase 1, DUT: dUTPase, DHF: dihydrofolate, DHFR: 127 
dihydrofolate reductase, NDPK: nucleoside-diphosphate kinase, NK: nucleoside kinase, 128 
NMPK: nucleoside monophosphate kinase, RNR: ribonucleotide reductase, SHMT: serine 129 
hydroxymethyltransferase, THF: tetrahydrofolate, TK: thymidine kinase, TS, ThyX: classical 130 
and flavin-dependent thymidylate synthase respectively, TMPK: dTMP kinase. 131 
 132 
  133 
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1. dUTPase inhibition 134 
The role of the dUTPase enzyme, catalyzing the hydrolysis of dUTP into dUMP and 135 
inorganic pyrophosphate is dual: on the one hand, it provides the dUMP precursor for dTTP 136 
de novo biosynthesis, while on the other hand, the enzyme keeps the level of cellular dUTP at 137 
a low value such that to prevent incorporation of uracil moieties into DNA [4]. This 138 
preventive action has great significance due to the suboptimal specificity of most DNA 139 
polymerases that will incorporate either dUMP or dTMP against the dAMP, simply depending 140 
on the cellular availability of dUTP versus dTTP. There are two major families of dUTPases: 141 
the trimeric dUTPases are especially widespread, while the dimeric dUTPases are found in 142 
some parasites and some phages (Figure 2) [4,5]. The overall structures as well as active site 143 
close-ups for these two dUTPase families are shown in Figure 2. In addition to the dUTP 144 
substrate, these active sites provide a specific environment for the catalytic water molecule 145 
that initiates nucleophilic attack at the - or -phosphorus atom (for trimeric, and dimeric 146 
dUTPases, respectively). Divalent metal ions also play an important role in the catalysis: in 147 
trimeric dUTPases, Mg(II) ion is present coordinating to the triphosphate chain, whereas in 148 
dimeric dUTPases, two divalent metal ions are involved in the catalytic steps. 149 
Considering that the human dUTPase also belongs to the trimeric family, the dimeric enzyme 150 
family (present in some parasites) perhaps provides a more straightforward dUTPase target, 151 
with potentially less side effects due to the large differences in the pathogen and host enzymes 152 
(cf Table 2). Such efforts singled out very effectively the dUTPases from Leishmania, 153 
Trypanosoma and Campylobacter species. Essentiality of dUTPases in these organisms was 154 
investigated and established in Trypanosoma brucei by RNAi [6]. In these cases, 155 
dissimilarities between the dUTP binding sites of the pathogen and the human enzymes 156 
presented a clear-cut starting point for development of drug candidates presumably showing 157 
less side effects [7–9]. Inhibitor design was performed by analyzing the high-resolution 3D 158 
crystal structures based on either small scale rational design or large scale in silico screening 159 
[10]. 160 
With regard to the trimeric family of dUTPases, two major pathogens were at the focus of 161 
relevant research efforts in targeting dUTPase (Table 2). Namely, Mycobacterium 162 
tuberculosis and Plasmodium falciparum, the causative agents of tuberculosis and malaria, 163 
respectively. In both of these organisms, the significance of the dUTPase enzyme in 164 
thymidylate biosynthesis is strongly enhanced due to the lack of salvage pathways [4,11]. The 165 
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3D structures of M. tuberculosis and P. falciparum dUTPases were published in 2004 and 166 
2005, respectively [12,13]. These structures formulated the basis for further studies. A quick 167 
and reliable dUTPase activity assay developed for M. tuberculosis dUTPases facilitated 168 
further high-throughput searches for inhibitor molecules potentially targeting species-specific 169 
segments in M. tuberculosis dUTPases [14]. An integrated approach starting from the ZINC 170 
molecule database and using more than 2 million drug-like compounds in a virtual screening 171 
provided a short list of promising candidates [15,16]. Importantly, this study utilized an 172 
innovative novel concept that can be possibly termed as “allosteric drug design”. Namely, in 173 
order to avoid potential side effects, the protein surface that was targeted in this study 174 
constituted by an essential species-specific segment of the mycobacterial dUTPase [17], in the 175 
vicinity of the highly conserved active site. The best performing drug candidates were 176 
successfully tested in in vitro assays and animal models (guinea pig) as well [15]. This 177 
approach showed a model case for a highly potential integrated method in drug design starting 178 
from the already available drug compound library. 179 
Similar high throughput searches were carried out in compound libraries of several thousands 180 
of candidate molecules for Plasmodium falciparum dUTPases [18]. The resulting 181 
considerations focused on the important observation that the uracil ring is of utmost 182 
importance in binding of ligands to the active site, whereas more variation is allowed at the 3’ 183 
and 5’ substituents [19]. Selectivity of the drugs against the pathogen and the human enzyme 184 
was also tested and the best performing drug candidates showed more than 200-fold 185 
selectivity [20]. This result is suggested to be further combined with transfer factors that may 186 
facilitate accumulation of the drugs within the parasite. Ongoing research in this field very 187 
recently focused on QSAR models facilitating design of novel compounds [21]. 188 
In spite of the vast number of studies and approaches there is still much to do in this field to 189 
arrive at a clinically tested drug candidate that may be the focus of further processes 190 
potentially resulting in approval of dUTPase inhibitors as antimicrobial drugs. 191 
 192 
 193 
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 194 
Figure 2. Comparison of trimeric and dimeric dUTPases. A) Cartoon representation of the 195 
trimeric Mycobacterium tuberculosis dUTPase (PDB ID:2PY4, [14]), chains colored by 196 
yellow, salmon and cyan. Substrate analogue dUPNPP shown as sticks with atomic coloring 197 
(carbon: black, oxygen: red, phosphorus: orange, nitrogen: blue) B) Cartoon representation of 198 
the dimeric Leishmania major dUTPase (PDB ID:2YAY, [7]), chains colored by yellow and 199 
cyan, substrate analogue dUPNPP shown as sticks with atomic coloring (carbon: black, 200 
oxygen: red, phosphorus: orange, nitrogen: blue). C) Active center of MtDut (PDB ID:2PY4, 201 
[14]), colored as in panel A, residues important for substrate binding and catalysis are shown 202 
as sticks with atomic coloring (carbon: colored by chain, oxygen: red, nitrogen: blue), 203 
catalytic magnesium and water as green and red spheres, respectively. Substrate analogue 204 
dUPNPP shown as sticks with atomic coloring as in Panel A. Dashed lines represent 205 
hydrogen-bonding interactions. D) Active center of LmDut (PDB ID:2YAY, [7]) colored as in 206 
Panel B, residues important for substrate binding and catalysis are shown as sticks with 207 
atomic coloring (carbon: colored by chain, oxygen: red, nitrogen: blue), catalytic calciums 208 
and water as green and red spheres respectively. Substrate analogue dUPNPP shown as sticks 209 
with atomic coloring as in Panel B. Dashed lines represent hydrogen-bonding interactions.  210 
Author manuscript published in: BBA - General Subjects 
12 
Table 2. Recent results on the inhibition of dUTPases 211 
Organism Year Summary Ref. 
Leishmania 
major 
1997 Identifying LmDut. 
Lysates of E. coli showed significant dUTPase activity increase after 
orthologous expression LmDut gene. 
[22] 
 2000  Verification of dimeric form of LmDut. 
dUDP and dUTP are both substrates of LmDut (dUDP is inhibitor of 
trimeric dUTPases). 
[23] 
 2001  Kinetic parameters of LmDut for dUTP hydrolysis are comparable to that of 
hDut. 
Dissimilarities in the binding of dUDP and dUMP as compared to the 
human enzyme suggest differences in the structure of the active sites. 
[24] 
 2011 
 
Crystal structure of LmDut in complex with substrate analogues, product 
dUMP, and a substrate fragment (dU).  
Very tight ligand binding pocket modifications at the uracil or ribose rings 
might perturb binding of an inhibitor. 
The presence of a single phosphate or similarly charged group is important 
to induce ligand binding conformation of LmDut. 
[7] 
Trypanosoma 
cruzi 
2004  Crystal structure of TcDut. 
Major differences between the substrate binding pocket of dimeric and 
trimeric dUTPases provides potential for selective inhibitor design. 
It was observed for the first time that ligand binding induces large 
conformational change in case of dimeric dUTPases. 
[8] 
 2006 
 
Inhibitor design based on in silico docking. 
No in vivo and in vitro effects of the compounds. 
Protein flexibility has to be taken into account. 
[10] 
Trypanosoma 
brucei 
2008 
 
The dimeric TbDut is a nuclear enzyme and down-regulation of its activity 
by RNAi proved that TbDut is indispensable for efficient cell cycle 
progression and DNA replication in T. brucei 
[6] 
 2013 
 
Conditional Dut knockout without adding thymidine caused impaired 
proliferation and lethality in T. brucei. 
Adding uracil, uridine or deoxyuridine could not rescue this phenotype. 
dUTPase has major role in the provision of pyrimidine nucleotides in 
kinetoplastids. 
[25] 
 2013  Crystallographic and NMR studies revealed that similarly to CjDut in case 
of TbDut nucleophilic attack also occurs on the β-phosphate of the substrate. 
Unlike in the trimer enzymes in case TbDut one of the divalent metal ions 
plays direct role in catalysis. 
[26] 
Campylobacter 
jejuni 
2004  The crystal structure of CjDut. 
Mg
2+
 is important in enzymatic action. It was shown for the first time, that 
nucleophilic attack occurs on the β-phosphate in contrast to the trimeric 
enzymes, where it happens at the α-phosphate.  
Ligand binding causes large conformational change so as in the case of 
TcDut [8]. 
[9] 
 2009  Difference in inhibition constants as compared to the trimeric dUTPase 
enzymes permits the design of specific inhibitors of CjDut. 
[27] 
 2011 Crystal structure of CjDut with dUPNPP substrate analogue contains only 
two metal ions at the active site, while in the dUPNP complex three of those 
[7] 
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were indentified. 
Glu49 is flipped away from the active site in the presence of the 
triphosphate, and no longer coordinates any of the metal ions. 
Mycobacterium 
tuberculosis 
2004  Crystal structure of MtDut reveals that its binding pocket is similar to that of 
hDut, hampering the design of MtDut specific inhibitors. 
Tris molecule in the trimer channel interface might be an inhibitor lead. 
[12] 
 2008  Identification of a bifunctional dCTP deaminase dUTPase in M. tub. 
Lower similarity to hDut and broader substrate specificity than MtDut 
marks this enzyme a possible target for chemotherapy. 
[28] 
 2008  Introducing a highly sensitive fluorescent label to follow the MtDut 
enzymatic reaction. 
Structure and activity of H145W MtDut is not altered.  
[14] 
 2011  Molecular modeling of MtDut nucleotide binding, based on activation 
energies from QM-MM modeling hydrolysis is slower than product release. 
[29] 
 2012  The dUTPase enzyme is essential in Mycobacterium smegmatis. 
Mycobacteria-specific loop has no major effect on MtDut activity in vitro, 
but a loop-specific function seems to be essential within the in vivo model 
M. smegmatis. 
[17] 
 2015  Virtual screening of several million small molecules against the species-
specific surface loop of MtDut was performed. 
An optimized hit was conjugated to a phagocytosis stimulating tuftsin 
peptide derivative and encapsulated into PLGA nanoparticles. 
In vivo efficacy of this formulation was verified in guinea pig model. 
[15] 
 2016 The prevention of DNA uracilation and the regulation of dNTP balance are 
decoupled in Mycobacteria and separately achieved by Dut and Dcd:dut 
enzyme functions, respectively. 
[30] 
Plasmodium 
falciparum 
2005  Development of selective inhibitor leads against PfDUT with antiparasite 
activity. 
Crystal structure of inhibitor bound PfDut. 
[13] 
 2005  Selective, nontoxic, drug-like inhibitor lead design against PfDut. 
Analogues of dUMP with variety of substituents at the 5’- and 3’-positions. 
Effectivity is not sufficient against Leishmania and Trypanosoma parasites. 
[31] 
 2006  Acyclic uracil derivatives with similar or better antiplasmodial properties 
then those in Ref [31] especially with regards to selectivity. 
Ki of best active compound was 0.2 μM.  
[32] 
 2007  Study of PfDut ligand binding. 
No significant conformational changes upon binding are inferred based on 
ITC measurements. 
[33] 
 2009  Tritylated uracil acetamide derivatives containing amide bond between the 
β-C and N-1 of uracil ring were found to be weak inhibitors of the PfDut. 
[34] 
 2010 
 
Study on PfDut and hDut kinetics. 
Specific product inhibition of the Plasmodium dUTPase compared to the 
human enzyme, was caused by the substituent at the C-5 position of the 
uracil ring. 
[35] 
 2011  In vitro HTS for PfDut inhibitors in a 3086 item compound library of 
commercially available non-proprietary compounds did not identify any 
hits. 
[18] 
 2011  Modification on the uracil ring of the tested compounds impaired inhibitory [36] 
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effect of those on PfDut. 
While there is room for variation of the 5’-trityl group and the 
3’-substituent. 
 2011  Testing β-branched acyclic uridine analogues as PfDut inhibitors.  
Ki of the best inhibitor was 0.5 μM. 
This showed more than 200-fold selectivity compared to hDut and EC50 = 
0.61 μM growth inhibition of P. falciparum. 
[20] 
 2011  Mutational analysis of residues important in binding of uracil based 
inhibitors containing trityl groups at the 5’-position. 
F46A mutation of PfDut leads to an increase in Ki values while K96A 
mutation has an opposite effect. 
[19] 
 2011  Testing lower lipophilicity and molecular weight diphenyl substituted 
inhibitors of PfDut. 
Slightly decreased activity against both dUTPase and parasite than the 
corresponding trityl derivatives was observed. 
[37] 
 2013  Characterization of novel conformationally restrained amide derivatives to 
overcome entropic disadvantages of former PfDut inhibitors. 
Inhibitors showed similar or greater potency but lower selectivity (<40x) in 
cellular assays, than the previous drug candidates against PfDut. 
[38] 
 2015  2D- and 3D-QSAR model using the LQTA-QSAR methodology on a series 
of PfDut inhibitors with high predictive power facilitates the design of new 
compounds with higher antimalarial bioactivities. 
[21] 
 212 
  213 
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2. Inhibition of thymidylate synthases 214 
Thymidylate synthase enzymes can be divided to two distinct categories: the so-called 215 
“classical” (TS) and flavin-dependent (ThyX) enzymes (Figure 3). These two types of 216 
thymidylate synthase enzymes share no mechanistic and structural similarity, however they 217 
perform the same enzymatic function (an interesting parallel to the two families of dUTPases, 218 
trimeric and dimeric). The flavin-dependent ThyX catalyzes FAD mediated methyl group 219 
addition to dUMP from 5,10-methylene tetrahydrofolate (CH2THF), resulting in dTMP and 220 
tetrahydrofolate in prokaryotes [39]. Recovery of CH2THF from the reaction products is 221 
performed by serine hydroxymethyltransferase. In contrast, in case of the classical 222 
thymidylate synthases (TSs), which are the product of gene tyms in eukaryotes and gene thyA 223 
in prokaryotic systems (often referred as ThyA), the methyl group is directly transferred from 224 
CH2THF to dUMP and the resulting dihydrofolate is recycled through the consecutive action 225 
of dihydrofolate reductase and serine hydroxymethyltransferase. The “classical” enzymes can 226 
be divided into two subgroups since some of those are bifunctional DHFR-TSs (Figure 3), 227 
although the TS domains of the bifunctional enzymes are highly similar to monofunctional 228 
TSs in terms of structure and catalytic mechanism. As a consequence of key importance of 229 
both kinds of thymidylate synthases in thymidine biosynthesis, those are subjects of extensive 230 
inhibitor design programs. 231 
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 232 
Figure 3. Comparison of catalytic mechanism and structure of different thymidylate 233 
synthases. A) Classical thymidylate synthase reaction cycle B) Structure of M. tuberculosis 234 
classical thymidylate synthase – MtTS (PDB ID: 4FOX) Protein is in cartoon representation, 235 
monomers colored cyan and salmon. dUMP and folate analogue inhibitor raltitrexed 236 
represented as sticks with atomic coloring (carbon: black, oxygen: red, phosphorus: orange, 237 
nitrogen: blue). Close up enlightens the ligand binding orientation. C) Structure of 238 
ChDHFR-TS (PDB ID: 4Q0D). Protein is in cartoon representation, TS domains with cyan 239 
and salmon, the corresponding DHFR domains with yellow and green. 5F-dUMP, and folic 240 
acid analogue 2XB (from Ref [40]) represented as sticks with atomic coloring (carbon: black, 241 
oxygen: red, phosphorus: orange, nitrogen: blue). Close up enlightens ligand binding 242 
orientation. D) ThyX mechanism according to ref. [39]. E) Thermotoga maritima ThyX (PDB 243 
ID: 4GT9) Protein is in cartoon representation, subunits of the tetramer colored cyan, blue, 244 
magenta and salmon. dUMP, CH2THF substrates and FAD cofactor represented as sticks with 245 
atomic coloring (substrate carbon: black, cofactor carbon: yellow, oxygen: red, phosphorus: 246 
orange, nitrogen: blue) To ease visualization, substrates from only two substrate binding 247 
pockets are shown. Close up enlightens ligand binding orientation of one of the active sites.  248 
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2.1. Inhibitors of classical thymidylate synthases 249 
Although the structure of the “classical” thymidylate synthases is highly conserved, several 250 
drug design programs still attempt to exploit the slight differences between pathogenic and 251 
human enzymes to design selective inhibitors of parasite TSs (Table 3). 252 
Comparing the structures of TS enzymes from bacteria and human it can be concluded that 253 
the conformation adopted by the enzymes upon binding of dUMP and folate-analog inhibitors 254 
is analogous [41]. The difference in the degree of active site closure could be a key to 255 
discriminate bacterial TSs against eukaryotic TSs and may provide basis for the design of 256 
species-specific non-folate analogues [41]. Towards this end Lactobacillus casei thymidylate 257 
synthase was studied as a model for TS enzymes from pathogens such as Enterococcus 258 
faecalis, Staphylococcus aureus and Bacillus anthracis, since the dimer interface loop region 259 
of these proteins is highly similar and both contain a small domain of fifty amino acids 260 
(residues 90-139 in LcTS), which is not present in the E. coli and human TSs [42–44]. 261 
 262 
First studies identified phenolphthalein and its derivatives as LcTS inhibitors with micromolar 263 
activity [45–47]. Extending the phthalimidic core resulted in 1,8-, 2,3- naphthalein 264 
compounds binding to LcTS at sub-micromolar concentrations while showing no detectable 265 
affinity for the human enzyme [48]. Several of these derivatives also showed selective 266 
antibacterial activity against other bacteria, such as S. aureus, Streptococcus and 267 
Cryptococcus neoformans in cell culture assays [49]. Nonetheless, crystal structures of 268 
complexes of C. neoformans and E. coli enzymes with one of the best active compounds did 269 
not provide a clear explanation for the origin of selectivity [50]. 270 
In parallel to these studies dansyl-tyrosine derivatives with micromolar affinities to bacterial 271 
TSs were identified as promising leads for drug design [51]. These compounds exploit the 272 
flexibility of the folate-binding site of bacterial TSs and possess enhanced specificity because 273 
of the interactions formed with non-conserved residues outside the active site of the bacterial 274 
enzymes [43,52].  275 
Subsequent development programs were focused only on the enhancement of the affinity and 276 
specificity of the naphthalein series. Optimization resulted in 1,2-naphthalein derivatives 277 
showing significant and dose dependent antibacterial potency against Staphylococcus 278 
epidermidis clinical isolate strains, without any signs of in vitro host toxicity and was also 279 
potent against Enterococcus faecalis and Staphylococcus aureus [53]. Importantly, the 280 
bacterial strains in this study were resistant to most of the best known antibacterial drugs, 281 
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including vancomycin, hence this inhibitor can be regarded as a promising future antibacterial 282 
agent [53]. 283 
Since the observed multiple binding modes of these naphthalein derivatives significantly 284 
impeded structure-based drug design, recent studies aimed to find inhibitors displaying a 285 
unique binding mode [54]. Therefore, starting from phenolphthalein, and following a 286 
retrosynthetic approach two compound libraries of two different scaffolds were designed [54]. 287 
X-ray crystallographic screening of the greatest potency hits revealed that some of those 288 
present in a common unique binding mode. Further improvement of these initial hits resulted 289 
in carboxamide derivatives with moderate, albeit specific potency against EcTS [55]. 290 
Following this deconstruction approach, drug design studies starting from a complex hTS 291 
inhibitor led to compounds, which displaced dUMP from its classical active site position in 292 
the ternary complex. One of these inhibitors showed Ki=0.31µM, and more than twenty-fold 293 
selectivity against PcTS [56]. Initial hits for the Enterococcus faecalis TS enzyme are also 294 
reported in the same study, which could be optimized in the future based on the recently 295 
published crystal structure of EfTS [57]. In addition the fact that 5-formyltetrahydrofolate co-296 
purifies with EfTS from cell extract and is observed at the active site of EfTS in the crystal 297 
structure raises fundamental questions about how the folate and thymidylate biosynthesis are 298 
coupled and regulated in these bacteria [57]. 299 
The thymidylate synthases of protozoan parasites like Plasmodia and Trypanosoma are fused 300 
to dihydrofolate reductase forming a bifunctional enzyme. In these cases drug development 301 
focuses mostly on DHFR inhibition (see section 3.2.). 302 
  303 
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Table 3. Recent results on the inhibition of classical thymidylate synthases (TS) 304 
Organism Year Summary Ref. 
Lactobacillus casei 
 
1999 
 
Several crystal structures of LcTS bound to dUMP and phthalimidic 
derivatives, which are designed to selectively inhibit TS enzymes 
of pathogenic species.  
[48] 
[49] 
 1999 
2001 
Structure-based design of dansyl-tyrosine derivatives, which 
specificly inhibit bacterial TSs, possibly due to interactions formed 
with non-conserved residues close to the active site. 
[51] 
[52] 
 2005 Molecular dynamics simulations explaining activity and species-
specificity of the best active compound from Ref [51] based on the 
predicted binding mode of the inhibitor to LcTS. 
[43] 
 2008 Changing the rigidity of dansyl-tyrosine derivatives oppositely 
alters effectivity of those against LcTS and EcTS. 
[58] 
 2011 Retrosynthetic method to design novel compounds exhibiting 
unique binding modes to LcTS led to promising candidates having 
single binding orientation. 
[54] 
Pneumocystis 
carinii 
2000 Based on the crystal structure the fungal specific β-sheet and the 
greater size of the active site of PcTS can be exploited for specific 
antifungal drug design. 
[47] 
 2003 Greater flexibility of parasite TSs compared to eukaryotic enzymes 
allow the design of specific antiparasite agents.  
[41] 
 2013 Following of a deconstruction synthesis approach starting from a 
complex hTS inhibitor resulted in novel specific inhibitors of PcTs 
with low micromolar affinity (best compound showed Ki of 0.31µM 
and more than 20-fold selectivity). 
[56] 
Enterococcus 
faecalis 
2006 In an extensive antibacterial TS inhibitor study a 1,2-naphthalein 
derivative proved to have MIC of 2.5µg/mL against E. faecalis. 
[53] 
 2011 Identification of a benzonitrile substituted dioxo-isoindol derivative 
as a good initial candidate for EfTS inhibitor design. 
[54] 
 2012 The crystal structure of E. faecalis thymidylate synthase serving as 
a basis of specific inhibitor development.  
5-formyltetrahydrofolate found at the active site of EfTS introduces 
questions about the connections between the folate and thymidylate 
biosynthesis in E. faecalis. 
[57] 
 2013 A retrosynthetic inhibitor design starting from a complex hTS 
inhibitor resulted in only moderately potent drugs against EfTS. 
[56] 
Staphylococcus 
aureus 
2006 Several 1,2- and 1,8-naphthalein acting as TS inhibitors were 
proven to have MIC of 0.5-5 µg/mL against S. aureus. 
[53] 
Staphylococcus 
epidermidis 
2006 During a thorough antibacterial TS inhibitor study a 
1,2-naphthalein derivative showing significant and dose dependent 
potency against S. epidermidis clinical isolate strains was 
identified. 
[53] 
 305 
  306 
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2.2. Inhibitors against flavin-dependent thymidylate synthase, ThyX 307 
ThyX, a thymidylate synthase with drastically different active-site geometries and distinct 308 
enzymatic mechanisms as compared to the classical TS isoenzymes, has been discovered in 309 
2002 [59–61]. The flavin-dependent ThyX applies a unique chemical cascade that does not 310 
follow the general scheme of biological methylation, but uses the following steps instead: i) 311 
activation of the nucleotide that involves no covalent modification but only electrostatic 312 
polarization of dUMP by the enzyme’s active site ii) methylene transfer from folate mediated 313 
by N5 of FAD [39] (Figure 3). As a consequence of the marked alterations in chemical 314 
mechanism from that of the classical thymidylate synthases along with the observed structural 315 
differences, inhibitors of classical TSs have only a reduced effect on ThyX enzymes [62–65].  316 
The exclusive existence of a distinct class of thymidylate synthase in a plethora of major 317 
pathogenic microorganisms including also Bacillus anthracis, Clostridium botulinum, 318 
Mycobacteria and Treponema pallidum, opened a new horizon for developing of antibiotic 319 
inhibitors with reduced toxicity [66] (Table 4). The emergence of mutations diminishing the 320 
effectivity of classical antifolate drugs against classical TSs of these organisms also 321 
underlines the high relevance of this novel approach [67]. Mutational studies showing that 322 
ThyX, but not the classical TS is essential in M. tuberculosis also supports the validity of the 323 
flavin-dependent enzyme as a drug development platform [68]. 324 
Structure based design is aided by crystal structures of ThyX enzymes from several species 325 
[62,65,69–75]. Extensive studies on numerous substituted deoxyuridine monophosphate 326 
derivatives resulted in drugs that clearly distinguished between MtThyX and MtTS and 327 
showed, albeit moderate, inhibition on MtThyX, but not on MtTS. However, some of these 328 
drugs also possessed dual potency being active against MtTMPK as well [76–80]. High 329 
throughput screens for non-substrate analogue inhibitors of ThyX activity, using Paramecium 330 
bursaria chlorella virus (PCBV)-1 ThyX, a well-studied model for flavin-dependent 331 
thymidylate synthases [63,81,82], resulted in several selective inhibitors of MtThyX and 332 
HpThyX [83]. One of these, namely 2-bromo-8-hydroxy-1,4-naphthoquinone also showed 333 
cellular activity against genetically modified E. coli strains in which the chromosomal copy of 334 
TS was replaced by PBCV-1 ThyX. Further derivatization of this compound led to drug 335 
molecules displaying high potency against Helicobacter pylori ThyX and showing also 336 
modest, but significant activity in an animal infection model [84]. Since other similar 337 
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naphthoquinone derivatives have already passed clinical trials this scaffold seems to be very 338 
promising target for ThyX inhibitor design [83].   339 
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Table 4. Recent results on the inhibition of flavin-dependent thymidylate synthase (ThyX) 340 
Organism Year Summary Ref. 
Thermotoga maritima 2003 Crystal structure of TmThyX reveals an common fold of ThyX 
family. 
[62] 
 2012 X-ray crystal structures of TmThyX with several folate 
derivatives are serving as useful models for drug design. 
The previously proposed mechanism of arginine mediated 
methylene transfer was eliminated by study of mutant R174K 
TmThyX enzymes. 
[73] 
 2013 Conformational change is essential for substrate binding of 
TmThyX. 
Compounds locking open conformation of the substrate-binding 
loop might act as specific inhibitors. 
[74] 
Paramecium bursaria 
chlorella virus-1 
 
2004 Analysis of FAD-dependent thymidylate synthase ThyX from 
PBCV supports that ThyX-specific inhibitors that do not affect 
classical TS enzymes can be designed. 
[63] 
 2006 Conformation of key residues at the active site of PBCV-1 ThyX 
differs from earlier reported ThyX structures, suggesting 
structural changes during catalysis.  
The reaction proceeds without methylene enzyme formation. 
[81] 
 2007 Report on benzoyl and triazole derivatives that demonstrated 
inhibition of the catalytic activity of PBCV1 ThyX. 
[82] 
  2-hydroxy-1,4-naphthoquinone derivatives (1,4-NQs) are tight 
binding inhibitors of PBCV-1 ThyX in vitro and in vivo. 
[83] 
 2014 Orchestrated fast reactions of the native substrates of ThyX, 
bypasses NADPH oxidase activity during the enzymatic reaction 
in aerobic microorganisms, enabling effective ThyX activity in 
oxygen rich cellular milieu. 
[85] 
Mycobacterium 
tuberculosis 
2004 MtTS mutations represent a pathway for development of 
antifolate drug resistance. 
[67] 
 2005 Crystal structure of MtThyX. 
ThyX enzymes are strongly conserved amongst evolutionarily 
distant organisms based on structural, functional and genomic 
comparisons. 
[69] 
 2006 Soaking of the crystal containing MtThyX-FAD-BrdUMP ternary 
complex into NADP+ solution results instead of a quaternary 
complex in a binary complex of NADP+ and Br-dUMP. 
For implication of data detailed mechanistic studies are required.  
[70] 
 2008 Extensive mutational study reveals a serine and a histidine as the 
key residues of MtThyX enzyme activity. 
It is still unclear which residues contribute to binding of 
methylenetetrahydrofolate (MTHFR) and NADPH.  
[86] 
 2008 Study of MtTS and MtThyX kinetics shows that both enzymes 
have low catalytic activity. 
A folate-based inhibitor revealed high selectivity against MtTS 
over MtThyX, entailing the possibility that reciprocal inhibitors of 
MtThyX may exist. 
[64] 
 2011 Testing substituted 2’-deoxyuridine monophosphate analogues 
against MtThyX. 
[76] 
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Best compound showed IC50=0.91 μM and lacked activity against 
MtTS (IC50 > 50 μM). 
 2012 Identification of weak MtThyX inhibitors, which exhibited no 
activity against MtTS 
Compounds were either substrate or inhibitor of MtTMPK, this 
simultaneous action might be advantageous for drug design. 
[77] 
 2012 2-hydroxy-1,4-naphthoquinone derivatives (1,4-NQs) inhibit the 
activity of MtThyX and HpThyX, but not that of hTS. 
Other 1,4-NQs have passed clinical trials, which designates this 
scaffold a very promising target for ThyX inhibitor design. 
[83] 
 2013 5-alkynyl uridine analogues in which the sugar moiety has been 
replaced by an acyclic phosphonate were designed against 
MtThyX based on binding model from NMR data. 
Weak inhibition of ThyX is achieved (43% inhibition at 50 μM 
inhibitor concentration). 
[78] 
 2015 C-5 modified nucleosides with antimycobacterial activity were 
tested against thymidylate synthases of M.tub. 
These showed lack of activity against the MtTS, while IC50 of the 
best compound against MtThyX was 8.32 µM. 
Mechanism of action of these compounds could only partially be 
associated with the inhibition of MtThyX. 
[79] 
 2015 Inhibition of MtThyX by 5-FU is contributing to the mechanism 
of anti-mycobacterial action of this drug. 
[87] 
 2015 High throughput crystallization of M. tuberculosis proteins 
resulted in structures of MtThyX bound to FAD and FdUMP 
deposited in the PDB. 
[75] 
 2016 Mechanism of ThyX action fundamentally differs from that of 
classical TSs. The folate in this case transfers the methyl group 
not directly to dUMP but to the flavin cofactor. This is a hitherto 
unseen methylation scheme. 
[39] 
Helicobacter pylori 2002 Identification of the first flavin-dependent thymidylate synthase 
in H. pylori. 
[59] 
 2004  Based on a mutational study Ser 84 in HpThyX is responsible for 
dUMP activation. 
[60] 
 2011,
2012 
Crystal structures and characterization of HpThyX enzyme aiding 
species specific drug design. 
[71] 
[72] 
 2015 2-hydroxy-1,4-naphthoquinone derivatives display potent 
inhibition of HpThyX activity.  
One of these has shown modest, but significant activity in an 
animal infection model. 
[84] 
  341 
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3. Dihydrofolate reductase inhibitors 342 
Dihydrofolate reductase is a well-validated therapeutic target of the folate pathway. There 343 
exist two major groups of these enzymes: the monofunctional DHFR and bifunctional 344 
DHFR-TS enzymes. 345 
3.1. Monofunctional DHFR 346 
Currently extensive studies are in progress against DHFRs of Pneumocystis and Mycobacteria 347 
since these parasites lack thymine salvage pathway and rely solely on de novo synthesis of 348 
this pyrimidine base [11,88] (Table 5). However, DHFRs of other pathogens also seem to be 349 
effective and highly studied targets (Table 5). 350 
3.1.1. Pneumocystis carinii 351 
The high resolution crystal structure of PcDHFR initiated structure-based inhibitor design 352 
against this enzyme [89]. Starting from piritrexim by replacing the carbon linker (C9) to 353 
nitrogen and adding a methyl group to form a triamine resulted in series of pyrido-pyrimidine 354 
compounds with enhanced selectivity against PcDHFR and TgDHFR-TS [90]. Structure 355 
analysis confirmed that this N9-methyl group interacts more favorably with Ile123 present at 356 
the substrate binding site of PcDHFR than with Val115, which resides at the same place in 357 
hDHFR [91]. Although optimization of the substituents of the phenyl ring attached to N9 358 
resulted in compounds with enhanced selectivity against both P. carinii and P. jirovecii 359 
DHFRs [92], the structure activity relationship is not fully apparent based on the enzyme-360 
inhibitor co-crystal structures [91]. Similar diaminoquinazoline derivatives in spite of 361 
showing higher effectivity were proven to be less selective against parasitic DHFRs as 362 
compared to pyrido-pyrimidines [93,94]. Studies of compounds with the arylthio-substitued 363 
furo-pyrimidine scaffold resulted in inhibitors with improved selectivity, however inadequate 364 
cellular uptake of these drugs prevented their further development [95]. This clearly indicates 365 
that studies on bacterial cell cultures and human cells assessing whole cell activity and 366 
toxicity are necessary to fully evaluate drug candidates against Pneumocystis species.   367 
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3.1.2. Bacillus anthracis 368 
The resistance of B. anthracis against trimethoprim promoted research for a potent inhibitor 369 
of DHFR of this bioterrorism agent parasite [96]. Testing of numerous classes of compounds 370 
resulted in some promising potent and selective hits [97,98], while some propargyl-371 
derivatives were turned out to be potent but not selective inhibitors of BaDHFR [99]. 372 
Structural information from crystallographic, NMR and mutational studies [100–102] 373 
combined with systematic analysis of substituents on the 2,4-diaminopyrimidine scaffold led 374 
to compounds with improved potency and selectivity against BaDHFR [103–109]. It has also 375 
been shown that efficiency can be further enhanced by applying the favored enantiomer 376 
instead of a racemic mixture of active compounds [106,109]. 377 
3.1.3. Enterococcus faecalis 378 
In case of E. faecalis the first studies about inhibitors against EfDHFR were recently 379 
published [110]. Investigation of 2,4-diaminopyrimidine derivatives proven to be active 380 
against BaDHFR [104], revealed that those are also potent inhibitors of EfDHFR. Modeling 381 
studies concluded that propargyl linked compounds may even be more suitable inhibitors of 382 
DHFR mutant E. faecalis strains. Since the mutation causing steric clash in case of other 383 
inhibitors does not affect these derivatives because of their better fit to the active site pocket 384 
of the dihydrofolate substrate [110]. 385 
3.1.4. Staphylococcus aureus 386 
The first line therapy of community-associated methicillin-resistant Staphylococcus aureus 387 
(CA MRSA) is a combined formulation under the brand name Bactrim targeting the folate 388 
biosynthesis of the bacteria, containing trimethoprim, a dihydrofolate reductase inhibitor and 389 
sulfamethoxazole, which is a dihydropteroate synthase inhibitor. However, emergence of 390 
DHFR mutations leading to trimethoprim resistant strains necessitates the development of 391 
novel inhibitors that effectively act against these mutant SaDHFRs to prolong the 392 
applicability of this class of antibiotics. Derivatization of trimethoprim resulted in a 5-benzyl-393 
2,4-diaminopyrimidine, Iclaprim, which showed favorable antibacterial activity on TMP-394 
resistant Staphylococcus aureus strains, and has reached phase 3 trials [111,112]. However 395 
these trials for the treatment of hospital-acquired, ventilator-associated, or health-care-396 
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associated pneumonia were terminated due to financial resource limitations
1
. Other 397 
2,4-diaminopyrimidine compounds proven to be effective inhibitors of B. anthracis DHFR 398 
were also tested against S. aureus. In spite of their favorable anti-staphylococcal potency, 399 
these leads were optimized later only against BaDHFR [105,113]. 400 
Propargyl-linked compounds with the same diaminopyrimidine scaffold, targeting DHFRs of 401 
various parasites were also optimized against SaDHFR [99,114,115]. These studies resulted in 402 
active and selective inhibitors of both wild-type and a TMP-resistant mutant enzyme [116–403 
120]. Based on these experiences development of inhibitors of Gram-negative bacteria, 404 
Klebsiella pneumoniae DHFR is also in the pipeline [121]. 405 
Derivatives containing the 2,4-diaminoquinazoline scaffold known for their high potency on 406 
PcDHFR and Trypanosomal DHFR-TSs [93,94,122], were parallelly developed against 407 
S. aureus and Mycobacteria. The inhibitors designed during this project were also very 408 
promising candidates for future therapies targeting SaDHFR [123,124]. However high serum 409 
binding of these compounds may decrease their in vivo efficacy. Recent in silico screening 410 
studies resulted in completely new scaffolds with favorable in vitro potency, initiating a new 411 
line of SaDHFR inhibitor design [125]. 412 
Recently it has been shown that exposure of DHFR targeting drugs induced hypermutator 413 
thymine auxotroph mutants [126,127], in which acquiring of antibiotic resistance was 414 
significantly more prevalent [128]. These phenomena might raise debates about the use of 415 
DHFR therapeutic pathway against S. aureus. 416 
3.1.5. Streptococcus mutans 417 
Trimetrexate analogues were identified as very potent inhibitors of S. mutans DHFR, a 418 
derivative with enhanced selectivity potently impaired cell growth and formation of S. mutans 419 
biofilms [129]. 420 
3.1.6. Mycobacterium tuberculosis 421 
In addition to the extensive efforts against Mycobacterial ThyX, classical DHFR inhibition is 422 
still applied against Mycobacteria. This approach is supported also by a recent verification of 423 
DHFR as a target of one of the first antituberculosis agents, para-aminosalicylic acid (PAS), a 424 
prodrug that after being activated by the folate pathway inhibits MtDHFR [130,131].  425 
 
1
 https://clinicaltrials.gov/ct2/show/NCT00543608?term=NCT00543608&rank=1 
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In this case however, it is questionable if MtDHFR inhibition acts via inducing thymineless 426 
cell death [132], since it has been proven that the flavin-dependent ThyX can provide enough 427 
dTMP for normal bacterial growth in a classical thymidylate synthase (MtTS) deficient strain 428 
[68], bypassing the need of MtDHFR. As an alternative explanation, disruption of the 429 
reactions centered around S-adenosylmethionione is suggested to be a primary cause of 430 
lethality of MtDHFR inhibitors [132]. This is also concordant with a model explaining 431 
resistance of M. tuberculosis cell lines defective in MtTS function to PAS, an inhibitor of 432 
MtDHFR [68,133]. In these mutant bacteria, more reduced folates remain available for other 433 
essential one-carbon addition reactions, which results in increased bacterial survival [131]. 434 
However, further studies are required to fully resolve this question. 435 
As PAS-resistant DHFR mutant M. tuberculosis strains are emerging and since PAS toxicity 436 
leads to gastrointestinal ailments, it is of great importance to find alternative MtDHFR 437 
inhibitors [134–137]. 438 
First trials against MtDHFR applied 1,6-dihydro-2,4-diamino-1,3,5-triazin derivative 439 
(WR99210) and its analogues, which have been proven to be potent against Mycobacterium 440 
avium [138]. These compounds were active in cellular assays, but unfortunately showed high 441 
toxicity in host cells which prevented their further development [139]. Aiming to identify 442 
inhibitors with better profiles certain studies hypothesized that filling the glycerol binding 443 
pocket observed in the crystal structures of human and M. tuberculosis DHFR by the inhibitor 444 
will enhance both potency and selectivity [140–142]. Pyrimethamine analogues with the triol-445 
mimicking trihydroxypentyl group were proven to be potent against MtDHFR [141], however 446 
no report is available about effects of those on M. tuberculosis growth. It is plausible that this 447 
hydrophilic modification prevents these hits to penetrate through the waxy mycobacterial cell 448 
wall, based on the fact that the inverse, lipophilic modification of methotrexate dramatically 449 
increased the whole-cell activity of the original molecule [132].  450 
Recently, a 2,4-diaminoquinazoline fragment was identified in a HTS search and was 451 
derivatized based on trimetrexate to have enhanced antimycobacterial potency [139,143]. 452 
Promising hits were also found amongst the compounds with 2,4-diamino-triazin and 453 
tetrahydro-1,3,5-triazin-2-amine scaffolds [144–147].  454 
The vast number of recent reports about inhibitor research against MtDHFR indicates that the 455 
extensive work has not yet resulted in a fully adequate candidate against this target. Further 456 
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drug development will hopefully lead to novel therapeutic agents to fight against drug 457 
resistant Mycobacterial species.  458 
3.1.7. Candida species 459 
While the TS enzyme of Candida species is not yet covered in literature, DHFR inhibitors 460 
were tested and fine-tuned against these fungi. The first potent inhibitors against CaDHFR 461 
were 1,3-diaminopyrrolo-quinazolines, which although being very effective both in vitro and 462 
in vivo were proven to be even more active against hDHFR [148]. In parallel the thorough 463 
optimization of 2,4-diaminopyrimidines resulted in a family of propagyl-linker containing 464 
derivatives, which are potent and selective inhibitors of CgDHFR and CaDHFR with 465 
significant antifungal effects and low host cell toxicity [115,149–154]. Nevertheless finding 466 
an adequate explanation for the observed inconsistencies between target inhibition and 467 
antifungal activity of these compounds in case of C. albicans [154] is of utmost importance 468 
for the future drug development programs. Still it is worth revisiting previously dismissed 469 
CaDHFR inhibitor leads with moderate in vitro activity, since it is possible that those have 470 
sufficient antifungal potency [154]. Recent modeling studies present a validated inverse 471 
docking method for compound selectivity prediction, which could also promote the 472 
development of these antifungal DHFR inhibitors [155].  473 
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Table 5. Recent results on the inhibition of monofunctional dihydrofolate reductases (DHFR) 474 
Organism Year Summary Ref. 
Pneumocystis 
carinii 
 
2008 Methyl or ethyl substitution of the linker N9 atom of the 
2,4-diaminoquinazoline inhibitors enhanced the potency of those. 
The original low selectivity of the compounds was unaffected. 
[94] 
 2010 Compounds having the arythio-substituted furo-pyrimidine scaffold 
resulted in PcDHFR inhibitors with improved selectivity, however these 
classical folates can not enter to P. carinii cells due to lack of transfer 
apparatus.  
[95] 
 2013 2,4-diaminopyrimidine derivatives methylated at the N9 linker were highly 
active and selective inhibitors of P. jirovecii and P. carinii DHFRs in 
vitro. 
[92] 
 2015 Enhanced potency and selectivity of the best compounds from Ref [92] is 
due to van der Waals interactions of the N9-methyl group at the active 
site.These are more favorable between Ile123 (present in both PcDHFR 
and PjDHFR) than those with the corresponding Val115 in hDHFR.  
Overall structure–activity correlations of inhibitors are less evident.  
[91] 
B. anthracis 2006 2,4-diamino-5-deazapteridine and pyrimidine derivatives showed in vitro 
activities against BaDHFR and effectively impaired growth of B. cereus. 
Selectivity of these inhibitors is to be enhanced. 
[97] 
 2007 2,4-diaminopyrimidine derivatives, attached to a dihydrophthalazine ring 
showed high potency and selectivity against BaDHFR and were also active 
against B. anthracis Sterne. 
Best compound referred later as RAB1. 
[98] 
 2007 Crystal structure of BaDHFR provides an accurate pharmacophore for 
structure based design of inhibitors. 
[100] 
 2008 Propargyl-linked 2,4-diaminopyrimidine derivatives were active against 
B. anthracis Sterne and potent but not selective inhibitors of BaDHFR. 
[99] 
 2009 Structure of BaDHFR in solution based on NMR measurements reveals 
flexible parts of the active site. 
[101] 
 2009 Crystal structure BaDHFR with RAB1 serves as structural foundation for 
development of derivatives with enhanced properties. 
[103] 
 2010 Identification of important active site contacts of BaDHFR inhibitors in a 
mutational and crystallographic study. 
[102] 
 2012
2014 
Derivatives with various substituents at the dihydrophthalazine moiety of 
RAB1 showing no major difference in potency and selectivity. 
[104] 
[107] 
 2013 Substitutions at the C6 position of the 2,4-diaminopyrimidine scaffold of 
RAB1 lead to compounds with attenuated potency against BaDHFR. 
[105] 
 2013 S-enantiomers of potent propargyl-linked 2,4-diaminopyrimidines 
inhibitors are more active against BaDHFR.  
Concentration of S-stereoisomer diluted by the R-enantiomer is to be 
considered during activity studies. 
[106] 
 2015 Identification of RAB1 sites which are sensitive to modification, 
substitution at these positions led to reduced potency. 
[108] 
 2015 Studies on derivatives with various substituents at the dihydrophthalazine 
moiety of RAB1showed that compounds with allyl and vinyl substituents 
are significantly more potent than RAB1 both in vitro and in vivo. 
[109] 
Enterococcus 2014 RAB1 analogues are potent inhibitors of EfDHFR and have promising [110] 
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faecalis whole-cell activity.  
Based on modeling results propargyl-linked inhibitors can be effective 
against EfDHFR mutants because those fit tighter to the site of the folate 
substrate. 
Staphhylococcus 
aureus 
2009 F98Y mutation in SaDHFR may be responsible for trimethoprim 
resistance through making favorable a second position for cofactor 
binding, which impedes inhibitor binding. 
[116] 
 2010 
2013 
B. anthracis inhibitor 2,4-diaminopyrimidine-dihydrophthalazine 
derivatives were potent against SaDHFR and presented anti-
staphylococcal activity.  
No report on further optimization of these compounds against S. aureus 
[113] 
[105] 
 2011 Structure-based design of 2,4-diaminoquinazoline derivatives against 
SaDHFR resulted in potent inhibitors with adequate antibacterial activity. 
Selectivity of the compounds is to be enhanced.  
[123]  
 2012 Propargyl-linked 2,4-diaminopyrimidines proved to be active against 
several parasites were fine-tuned against MRSA and S. pyogenes by the 
incorporation of additional pyridyl-heterocycles. 
The resulting potent inhibitors of SaDHFR and SpDHFR were also active 
against clinical isolates of several antibiotic resistant Staphylococcal 
strains. 
[117] 
 2012 Resistance mutations in SaDHFR were induced by propargyl-linked 
2,4-diaminopyrimidine derivatives with moderate frequency. Effectivity of 
these inhibitors decreased by the mutations however the resulting MICs 
are still acceptable (2.5 µg/ml). 
[118] 
 2013 Crystal structures of hDHFR with propargyl-linked 
2,4-diaminopyrimidines of high antibacterial potency serve as a basis for 
selective inhibitor design. 
[119] 
 2014 Attaching a 7-substituted-benzimidazol-1-yl moiety to the 2,4-
diaminoquinazoline scaffold led to highly selective SaDHFR inhibitors 
with great potency against S. aureus. 
High serum binding might significantly reduce the level of in vivo efficacy 
of these compounds. 
[124] 
 
 
2014 Multiple virtual screenings of large compound libraries for SaDHFR 
inhibitors resulted in hits with promising anti-staphylococcal properties. 
Those were found to be active against SaDHFR but not toxic against 
mammalian cells. Development of these novel scaffolds is in progress. 
[125] 
 2015 Potency of enantiomers of propargyl-linked 2,4-diaminopyrimidine 
derivatives against SaDHFR is significantly different from each other. 
[120] 
 2015 Trimethoprim-sulfamethoxazole antifolate therapy triggers SaTS 
mutations leading to thymine-dependent small colony variant formation, 
which is less virulent, but more persistent than the wild type bacteria. 
[127] 
Klebsiella 
pneumoniae 
2014 Propargyl-linked 2,4-diaminopyrimidine derivatives inhibit KpDHFR and 
impair Klebsiella pneumoniae cell growth. Crystal structures of KpDHFR 
with these compounds will aid the design of compounds with enhanced 
selectivity. 
[121] 
Streptococcus 
mutans 
2014 Identification of trimetrexate analogues against SmDHFR resulted in 
compounds, which selectively (SI>100) inhibited cell growth and 
formation of S. mutans biofilms.  
[129] 
Mycobacterium 
tuberculosis 
2000 Inhibitor bound three-dimensional structure of MtDHFR aids structure 
based drug design against this target enzyme. 
[140] 
 2002 First proof that besides being active against M. avium the dihydro- [138] 
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diamino-triazin derivative WR99210 potently impairs M. tuberculosis cell 
growth via MtDHFR inhibition. 
 2007 Pyrimethamine analogues having triol substituents accommodating the 
glycerol binding site of MtDHFR were proven to be potent inhibitors of 
the enzyme. 
[141] 
 2012 A 2,4-diaminoquinazoline fragment was identified in a HTS project as a 
potent MtDHFR inhibitor and showed promising target specific effects in 
cellular assays. 
[139] 
 2013 Antimalarial drug para-aminosalicylic acid (PAS) perturbs folate 
metabolism in M. tuberculosis as a prodrug, which after bioactivation by 
other enzymes of the folate pathway acts as a MtDHFR inhibitor. 
[130]
[131] 
 2014 Missense mutations residing within the active site coding region of 
dihydrofolate synthase, one of the PAS activation enzymes, found in 
clinical isolates of M. tuberculosis were identified as the causative of PAS 
resistance. 
[134] 
 2014 Unlike methotrexate its diester derivatives with increased lipophilicity 
exhibited significant whole-cell potency against M. tuberculosis possibly 
because of enhanced penetration rate. 
It is suggested that these derivatives act through the disruption of methyl-
transfer mediated by S-adenosylmethionione.  
[132] 
 2014 
2015 
Development of 2,4-diamino-triazin derivatives resulted in MtDHFR 
inhibitors with favorable whole cell activity against Mtb (MIC < 2μM) 
along with low and moderate cytotoxicity.  
[144]
[145]
[146] 
 2015 Minireview on mechanism of PAS action and resistance.  [135] 
 2015 Study of a focused library including more than 2000 compounds identified 
a 2,4-diaminoquinazoline derivative with promising in vivo antitubercular 
efficiency and low host cell toxicity. 
[143] 
 2015 Modeling study on MtDHFR proposed selective and potent agents against 
MtDHFR. 
[142] 
 2015 In silico screening for MtDHFR inhibitors identified two compounds with 
the tetrahydro-1,3,5-triazin-2-amine scaffold, which were active against 
M. bovis BCG (MIC < 5µM). 
[147] 
 2016 Mutation resulting PAS resistance in M. tuberculosis revealed that gene 
Rv2671 was misannotated. Overexpression of Rv2671 protein resulted in 
bacterial escape of PAS treatment, which observation led to the discovery 
that this protein is a DHFR.  
[136] 
Candida glabrata 
Candida albicans 
1996 Development of 1,3-diaminopyrrolo-quinazolines against C. albicans 
resulted in compounds with great in vivo and in vitro potency. 
However these were even more potent against hDHFR and toxic for HCT 
cell lines. 
[148] 
 2004 Inconsistencies were found in the case of drugs targeting C. albicans 
between the effect of those on CaDHFR activity and on parasite growth. 
Designed compounds were found to be potent but not selective. 
[149] 
 2008 
 
Based on CgDHFR crystal structure two drugs possessing subnanomolar 
potency against the enzyme and significantly impairing C. glabrata growth 
were designed. 
These were also highly selective in vitro and showed low toxicity against 
mammalian cells. 
[115] 
 2009 
 
Structure activity relationship study of propargyl-linked 
1,3-diaminopyrimidines targeting CaDHFR. 
[150] 
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Antifungal activity is still not well correlated with CaDHFR inhibition. 
Resulting compounds are toxic to human cells in the concentration 
effective against C. albicans. 
 2009 Derivatives of the best active 1,3-diaminopyrimidine compounds from 
Ref [115] were outperformed by the unmodified compounds in terms of 
activity against CgDHFR  
In the crystal structures of CgDHFR only R-enantiomers of the inhibitors 
were found in the active center. 
[151] 
 2011 
 
Structure based study on improving the affinity of moderately potent 
compounds from Ref [150] against CaDHFR. 
Increasing hydrophobicity at certain positions enhanced the extent of the 
van der Waals contacts. 
[152] 
 2013 
 
Replacing a phenyl group of the best active compounds from Ref [115] 
with aromatic or alicyclic heterocycles resulted in derivatives with 
decreased efficiency of CaDHFR inhibition and selectivity ratios. 
[153] 
 2014 
 
Three compounds from a set of novel propargyl-linked 
1,3-diaminopyrimidines proved to possess outstanding antifungal activity 
(MIC<1 μg/mL) and in vivo selectivity. 
[154] 
 2016 Validation of an in silico inverse docking method for predicting selectivity 
of CaDHFR inhibitors. 
[155] 
  475 
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3.2. Bifunctional DHFR-TS 476 
Protozoa encode bifunctional DHFR-TSs, in which the TS domain is fused to the carboxy 477 
terminal of the DHFR domain by a junction peptide of varying size. Thus the two enzyme 478 
domains do not share a common folate binding site, unlike in the case of bifunctional dCTP 479 
deaminase – dUTPase [28]. The fusion of the two proteins facilitates dihydrofolate 480 
elimination through metabolic channeling and allows sufficient coordinate control of folate 481 
metabolizing enzymes, which might represent a biological advantage of such bifunctional 482 
DHFR-TSs [156]. The junction of the two proteins is generally not considered as the source 483 
of differences in drug actions, which is rather assigned to the sequence diversity [157,158]. 484 
Although this flexible linker does not influence the action of classical antifolates it might be a 485 
subject of specific inhibitor design, since it modulates enzyme activity in some specific cases 486 
[159,160]. Compounds binding to the dimer interface and acting as allosteric inhibitors of 487 
DHFR-TSs are also in the scope of drug design projects [161,162]. Still, the main approach 488 
targeting these bifunctional DHFR-TS enzymes is the development of specific DHFR 489 
inhibitors (Table 6). 490 
3.2.1. Plasmodium species 491 
Fast adaptation of Plasmodium falciparum DHFR-TS by specific mutations in the active site 492 
triggers continuous drug development programs against the emerging mutant enzymes.  493 
In most cases mutations which led to drug-resistance were associated with steric exclusion of 494 
the conformationally constrained inhibitors. Based on this observation compounds with 495 
increased flexibility have been developed against PfDHFR-TS to overcome fast adaptation of 496 
the parasite [163]. Combination of this principle and structure based drug design aided by 497 
crystal structures of substrates and inhibitors in complex with wild-type and quadruple mutant 498 
PfDHFR–TS resulted in compounds which inhibit both the wild type and the mutant 499 
protozoan enzyme [163–165]. It has also been shown that one of the derivatives, namely 500 
P218, displays in vivo activity against wild-type and pyrimethamine-resistant malarias [163]. 501 
Since the pre-clinical safety studies have been completed for the drug candidate P218, it may 502 
proceed to first in-human tests
2
, meanwhile a recent molecular modeling analysis might 503 
facilitate the synthesis of P218 derivatives with enhanced performance [166]. In parallel with 504 
 
2
 MMV (Medicines for Malaria Venture) Research and Development 
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these studies new scaffolds for inhibitor design against PfDHFR-TS were also studied to 505 
different extents [166–170]. 506 
Besides mutations in PfDHFR–TS, it has been shown that gene amplification of GTP-507 
cyclohydrolase, the first enzyme in the folate synthesis pathway of the parasite, is strongly 508 
associated with antifolate drug resistance, revealing this enzyme as a potential new target to 509 
be considered for antimalarial drug design [171]. 510 
3.2.2. Leishmania 511 
While the Plasmodium enzyme is the target of pyrimethamine, one of the few clinically active 512 
anti-malarial agents, this drug despite the high similarity of protozoan TS-DHFRs is 513 
ineffective to treat leishmaniasis. This difference in pyrimethamine inhibition is associated 514 
with the observation that this drug acts on the DHFR domain which – unlike the highly 515 
conserved TS domain – is more variable between species, albeit these differences are much 516 
smaller, than those between the human and protozoan enzymes. Other common antimicrobial 517 
DHFR inhibitors such as cycloguanil and trimethoprim were also not effective against 518 
Leishmania.  519 
In Plasmodium point mutations in the DHFR gene are the source of pyrimethamine resistance, 520 
while Leishmania acts against antifolates by amplification of the gene encoding DHFR [156]. 521 
As such it is expected that Leishmania is less capable to develop resistance-inducing 522 
mutations.  523 
Some quantitative structure activity relationship schemes of some antifolates against L. major 524 
have already been established in early studies, however, these were abandoned, possibly 525 
because of insufficient selectivity profile of the compounds [172,173]. Later, during the 526 
development of Trypanosomal DHFR-TS inhibitors some moderately active inhibitors of 527 
L. infantum and L. donovani have been reported [122,174]. The structure of LmDHFR-TS has 528 
been solved, albeit the crystallographic data is not available in Protein Data Bank [158]. 529 
Recent studies report only in silico testing of limited set of compounds against homology 530 
models of L. donovani chagasi and L. major [158,175,176]. However recently promising 531 
preclinical development candidates against L. donovani exhibited moderate inhibition of 532 
LdDHFR-TS and inhibitory effects on promastigotes and amastigotes by triggering their 533 
apoptotic cascade [177]. 534 
3.2.3. Trypanosomas 535 
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To overcome drug resistance of T. cruzi, T. brucei and L. infantum series of compounds were 536 
tested against DHFR-TS of these parasites, which resulted in good activity and selectivity 537 
leads against the protozoan enzymes [174]. Pyrimidine analogues including trimetrexate, a 538 
DHFR inhibitor used in pneumocystis pneumonia therapy, were active in vitro but exhibited 539 
only limited activity in vivo [178,179]. Diaminoquinazoline derivatives showed a more 540 
promising in vivo profile [122,180] and hence these are in the focus of extensive structure 541 
based drug design [181–185]. Based on these studies potent inhibitors against Trypanosomal 542 
DHFR-TSs have already been developed, however overcoming selectivity problems is still a 543 
challenge. 544 
3.2.4. Toxoplasma gondii 545 
Comprehensive research has been performed to find selective inhibitors against Toxoplasma 546 
gondii DHFR-TS as a validated drug target [186]. Since Toxoplasma cannot salvage dTTP 547 
from an extracellular source, indirect inactivation of thymidylate synthase via DHFR 548 
inhibition is lethal to the parasite [187]. The design of TgDHFR-TS inhibitors has largely 549 
relied on in vitro screening and homology modeling [114,188–190], where fine-tuning of 550 
human DHFR inhibitors against the T. gondii enzyme resulted in some potent and selective 551 
drug candidates [190]. Future studies will be directed towards improving the best active 552 
tricyclic pyrimido[4,5-b]indole scaffold based on the comparison of the recently determined 553 
crystal structures of TgDHFR-TS with its human counterpart [190,191].  554 
Exploiting this structural information research projects aiming to identify allosteric inhibitors 555 
targeting the TS-TS dimer interface of the TgDHFR-TS have also been launched [190,191]. 556 
The moderately potent compounds reported from these studies serve as proof-of-concept and 557 
may lead to design and optimization of novel class of potent and selective inhibitors to treat 558 
toxoplasmosis [161,162]. 559 
3.2.5. Cryptosporidium hominis  560 
The crystal structure of Cryptosporidium hominis DHFR-TS was determined in the early 561 
2000s [192,193], enabling structure based drug design of selective inhibitors of the enzyme. 562 
Derivatization of trimethoprim by applying a propargyl linker resulted in novel series of 563 
classical antifolates with nanomolar inhibitory constants (Ki) against ChDHFR-TS [114,194] 564 
and remarkable in vivo activity [40,195]. However, difficulties were observed in transport of 565 
the best potent compound through the vacuolar membranes of the parasite [40], which could 566 
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be overcome by loading the inhibitor into PLGA nanoparticles fused to Cryptosporidium 567 
specific antibody [196]. Future development strategies will focus on improving the selectivity 568 
against the human enzyme without compromising the activity against ChDHFR-TS by 569 
applying computer-aided design [40]. 570 
It has been shown that mutations in the linker region, especially inside the crossover helix of 571 
the C. hominis DHFR, impair the catalytic rate of the enzyme, which implies that the linker is 572 
necessary for optimal dihydrofolate reductase activity. Initiated by this finding, studies 573 
applying virtual screening and structure based design independently resulted in mid-574 
micromolar allosteric inhibitors [159,160]. Subsequent synthetic development of these proof-575 
of-concept compounds to possess higher affinity to the identified surface cleft will 576 
presumably eventuate in more potent, novel inhibitors against ChDHFR-TS. 577 
  578 
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Table 6. Recent results on the inhibition of bifunctional dihydrofolate reductase – thymidylate 579 
synthases 580 
Organism Year Summary Ref. 
Plasmodium 
falciparum 
1997 Identifying mutations responsible for drug resistance of PfDHFR-TS. [197] 
 2003 Crystal structure of wild-type and mutant PfDHFR-TS enzymes serves as 
templates for designing novel drugs against resistant-mutant parasites. 
Junction region might be a target for selective inhibitors interfering with 
interdomain interactions. 
[164] 
 2004 Report on low nanomolar level inhibitors targeting the mutant enzymes 
with good antimalarial activities against resistant P. falciparum parasites 
and low or moderate cytotoxicity candidates for novel antimalarials. 
[198] 
 2009 Novel inhibitors with guanidine scaffold were found to be active against 
wild-type and mutant PfDHFR-TS enzymes. 
Co-crystal of novel inhibitors with a drug-resistant mutant PfDHFR-TS. 
[199]  
 2010  Drug candidate, QN254 however showed relative in vitro selectivity 
towards the Plasmodium DHFR enzyme possesses inadequate 
therapeutic index tested in rats. Compound relinquished. 
[200] 
 2012 Identification of selective and potent inhibitors of wild-type and mutant 
PfDHFR-TS enzymes, with good metabolic properties. 
Compound P218 was denominated as a pre-clinical candidate. 
[163] 
 2013 4,6-diaryl-2-aminopyrimidine derivatives proved to be promising leads 
for inhibitor design against PfDHFR-TS. 
[167] 
 2014 Compounds from Brucea mollis Wall. ex kurz were in silico checked 
against wild type and mutant Pf DHFR-TS. 
Inhibitors with better binding affinity than pyrimethamine were 
identified. 
[168] 
 2014 Molecular dynamics simulation of interactions between rigid and flexible 
antifolates of wild-type and pyrimethamine-resistant mutant of 
PfDHFR-TS. Description of key inhibitor binding residues. 
[169] 
 2014 Molecular dynamics analysis of inhibitor P218 binding to wild-type and 
mutant PfDHFR-TS. 
[166] 
 2014 Guanylthiourea derivatives with IC50 value of 100 µM and 400 nM were 
developed against PfDHFR-TS. 
[170] 
Plasmodium ovale 2012 Antifolate drugs showed similar kinetic and sensitivity profiles with 
PoDHFR-TS as compared to those of the P. falciparum and P. vivax 
enzymes. 
[201] 
Plasmodium vivax 2001 Transgenic Plasmodium lines expressing PvDHFR-TS for screening 
anti-P. vivax compounds targeting this enzyme. 
[202] 
 2006 Testing compounds on a PvDHFR-TS-dependent bacterial strain, 
revealed that inhibitors of this enzyme are similar to those of 
PfDHFR-TS. 
Adequate correlation was found between the in vitro enzyme inhibition 
constants and the IC50 values. 
[203] 
Leishmania major 2012 In silico modelling study of LmDHFR-TS and virtual screening for its 
inhibitors. 
[176] 
 2012 
 
Promising preclinical development candidates with moderate inhibition 
of LdDHFR-TS showed inhibitory effects on L. donovani promastigotes 
[177] 
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and amastigotes by triggering of the apoptotic cascade. 
Leishmania 
donovani 
1999 Series of compounds were tested against T. cruzi, T. brucei and 
L. infantum DHFR-TS. Leads for drug development with good activity 
and selectivity against the protozoan enzymes were identified. 
[174] 
 2010 Modeling the structure of Leishmania donovani chagasi DHFR-TS to aid 
future drug design programs. 
[175] 
Trypanosoma 
brucei, cruzi 
2002 2,4-diaminopyrimidines are potent inhibitors of the Trypanosomal 
DHFR-TS enzymes in vitro, but show only limited activity in vivo.  
[178] 
[179] 
 2005 The quinazoline derivative antifolate, trimetrexate is proven to a potent 
but not selective inhibitor of TcDHFR-TS. 
Outset of drug development is the improvement of the selectivity of this 
compound. 
[180] 
 2005 2,4-diaminoquinazoline-based compounds inhibited TcDHFR-TS and 
TbDHFR-TS and have in vivo activity in a rodent model of Chagas 
disease, but lack activity against the L. donovani. 
[122] 
 2008 First crystal structures of apo and inhibitor bound TcDHFR. 
3D-QSAR analysis of inhibitors of TcDHFR activity. 
Identification of several highly potent inhibitors of TcDHFR from 
libraries of antifolate compounds. 
[181] 
[182] 
[183] 
 2010 Introducing chemical modifications on trimetrexate did not resulted in 
additional favorable contacts with TcDHFR nor disfavor hTS binding. 
[184] 
 2011 First Crystal structure of DHFR domain of TbDHFR with NADPH and 
inhibitors. 
TbDHFR is similar to pyrimethamine resistant mutant PfDHFRs. 
During inhibition design steric hindrance of Thr86 clash should be 
considered  
[185] 
Toxoplasma  
gondii 
2002 De novo pyrimidine biosynthesis is essential for virulence of T. gondii. [186] 
 2007 Rational lead design based on homology model of TgDHFR-TS and 
crystal structure of ChDHFR-TS. 
Change of the one carbon linker in trimethoprim with a longer but rigid 
propargyl linker to access hydrophobic pocket of DHFR active site 
resulted in compounds displaying high potency and selectivity against 
TgDHFR-TS and ChDHFR-TS. 
[114] 
 2008 Among potent compounds constructed during the development of 
inhibitors against hTS, a class of derivatives was proven to be only 
marginally active on the human target.  
These however showed high potency and selectivity against 
TgDHFR-TS.  
[188] 
 2013 Comparative docking to the homology model of TgDHFR-TS applying 
different softwares for screening the same drug library resulted in several 
potential inhibitors of this enzyme. 
[189] 
 2013 First crystal structure of TgDHFR-TS aiding structure based inhibitor 
design. 
[191] 
 2013 Compounds with single-digit nanomolar Ki for TgDHFR-TS, with 28- 
and 122-fold selectivity over human TS (hTS) were synthesized on the 
basis of the potent bicyclic hTS inhibitor nolatrexed. 
[190] 
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 2013 β-strand mimicking peptides that target dimer interface of TgDHFR-TS 
inhibit enzymatic activity in a species-specific manner. 
Non-conserved residues in the linker between TS and DHFR play a key 
role in domain–domain communication and in peptide interaction. 
[162] 
 2013 In silico screening for allosteric inhibitors at the interface between the 
two TS domains. 
Identified compounds showed moderate inhibition of TgDHFR-TS but 
no selectivity against hTS. 
[161] 
Cryptosporidium 
hominis 
2003, 
2005 
Crystal structures of ChDHFR-TS revealing protein-ligand interactions 
provide template for structure-based drug design against ChDHFR-TS. 
[192]
[193]  
 2007 Highly efficient inhibitors of ChDHFR-TS (cf. at T. gondii). [114] 
 2008 Structure-based inhibitor development resulted in enhanced affinity 
compounds from Ref. [114] against ChDHFR-TS, without compromising 
selectivity.  
[194] 
 2009 ChDHFR-TS crossover helix is indispensable for adequate enzyme 
activity since mutations in this region resulted in a drastic reduction of 
catalytic rate. 
[204] 
 2008 Novel non-active site inhibitors with mid-micromolar potency against of 
ChDHFR-TS were identified by a virtual screening revealed inhibitory 
potential of an allosteric pocket of this enzyme. 
[159] 
 2013 Small molecule compound binding at the species-specific helical protein 
interaction surface could result in catalytic inhibition and enzyme 
destabilization. 
[160] 
 2013 A novel series of classical antifolates, were proven to be potent inhibitors 
of ChDHFR-TS.  
Inhibitor bound crystal structure reveals key structural differences 
between ChDHFR-TS and hTS and aids the design of parasite specific 
agents.  
[195] 
 2014 Identification of a potent inhibitor of ChDHFR-TS with anti-
cryptosporidial activity in cell culture. 
Difficulties in delivery of the potent compounds through the vacuolar 
membranes of the parasite were observed. 
[40] 
 2015 PLGA nanoparticles fused to Cryptosporidium specific antibodies loaded 
with a potent inhibitor of ChDHFR-TS specifically targeted the parasite.  
This formulation reduced the level of parasites by 200-fold in cell culture 
as compared to the 4.4-fold decrease upon normal inhibitor addition. 
[196] 
 581 
  582 
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4. Other promising targets 583 
4.1. Serine hydroxymethyltransferase inhibitors 584 
Since serine hydroxymethyltransferase (SHMT) plays a key role in the dTMP synthesis 585 
(Figure 1) it is a highly relevant target for antiparasite drugs. Still, inhibitor development was 586 
only reported in the case of Plasmodium SHMT, which enzyme was validated as an 587 
antimalarial platform [205–209]. Differences in the structure of the ligand binding pockets of 588 
human and Plasmodium SHMTs have been exploited during the design of species-specific 589 
inhibitors against the protozoal enzyme [209]. The excessive efforts for developing PfSHMT 590 
inhibitors resulted in leads with high selectivity margin relative to mammalian cell lines and 591 
active also against the tested multidrug resistant Plasmodium falciparum strains [210,211]. 592 
However further studies are required to enhance the low metabolic stability of the best active 593 
PfSHMT inhibitors.  594 
Characterization of Mycobacterial and Trypanosomal SHMTs have been performed, as a first 595 
step of drug design against these enzymes [212–217]. It has been shown that unlike 596 
eukaryotic SHMTs including those of other trypanosomatids, T. cruzi SHMT does not 597 
oligomerize in solution [217]. While the genome of M. tuberculosis encodes two different 598 
dimeric SHMTs, which also differ from the tetrameric mammalian enzymes [212,213]. In 599 
most SHMTs except, among others, the Mycobaterial enzymes, a strictly conserved lysine 600 
forms covalent bond with the cofactor pyridoxal phosphate. Mycobacterial SHMTs uniquely 601 
display significant changes in the conserved threonine-rich octapeptide sequence near this 602 
active site lysine residue [212,213], which might explain the slightly distinct catalytic 603 
properties of these enzymes compared to other SHMTs.  604 
These marked differences of T. cruzi and Mycobacterial SHMTs to other isoenzymes might 605 
facilitate specific drug development against these targets, whereas the high similarity between 606 
Leishmanial and human SHMTs renders the design of specific inhibitors of LdSHMT 607 
challenging [214,215]. 608 
  609 
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4.2. Thymidine kinase inhibitors 610 
It has been proven that the pyrimidine nucleotide salvage is indispensable in vivo, by 611 
knocking out thymidine kinase (TK) the key enzyme of the pathway in mice [218]. Thus TK 612 
is also a potential objective of antiparasite drug development [218–222]. Such as in the case 613 
of Cryptosporidium parvum, thymidine kinase is found to be an effective target in anti-614 
cryptosporidial therapy [222], since the treatment of the bacteria with fluorinated pyrimidine 615 
derivatives processed by the pro-drug activator CpTK resulted in inhibition of parasite growth 616 
in an in vitro model of infection and was found effective in a mouse model, as well.  617 
Leishmania major TK (LmTK) knockout mutants also showed lower proliferation rates, 618 
morphological defects and were found to be less infective [219]. However, a recent 619 
crystallographic study revealed that the active site of LmTK is analogous to that of the human 620 
enzyme [220]. This is also demonstrated by the highly similar kinetic parameters associated 621 
with the binding of substrates and inhibitors, depicting the design of selective LmTK-specific 622 
inhibitors even more elusive. 623 
While T. brucei thymidine kinase (TbTK), which was shown to be a pseudo-dimer of 624 
covalently linked tandem repeat of monomers, has broader substrate specificity than the 625 
human enzyme and is therefore a more feasible drug target [221].  626 
Thymidine kinase inhibition is not applicable against several parasites including 627 
Pseudomonas aeruginosa, Helicobacter pylori, Toxoplasma gondii and Mycobacteria which 628 
do not encode this enzyme [11,187], although the lack of thymine nucleotide salvage 629 
sensitizes these organisms for inhibitors of the de novo synthesis pathway.  630 
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4.3. Thymidylate kinase inhibitors 631 
As TMPK catalyses the formation of dTDP from dTMP, it is essentially important in the 632 
dTTP synthesis pathway for DNA synthesis, and also as an antiparasite drug target [223]. 633 
Inhibition of Staphylococcus aureus TMPK has resulted in in vivo anti-staphylococcal 634 
efficacy in mouse model and the inhibitor molecule was proven to be selective against the 635 
human enzyme [224,225]. Compounds with nanomolar inhibition potency against 636 
Pseudomonas aeruginosa thymidylate kinase have also been developed, however those were 637 
ineffective against the bacteria possibly due to poor penetration of the drug through the 638 
complex cell membrane [226]. Investigation of thymidine monophosphate analogs against 639 
MtTMPK resulted only in very weak inhibitors [227,228], whereas compounds with 640 
thymidine core and their acyclic bioisosteres were found to be more promising lead 641 
candidates with micromolar or lower inhibitory constants (Ki) and favorable selectivity [229–642 
231]. Recently three novel compound series were also tested against MtTMPK [232]. The 643 
development of 1,6-naphthyridinone compounds has not led to high potency MtTMPK 644 
inhibitors, thus the focus was shifted to cyanopyridones. These showed single digit nanomolar 645 
in vitro activity, but were ineffective in cellular assays. The third series containing sulfoxide 646 
or sulfone substituents showed anti-mycobacterial activity at low micromolar concentrations. 647 
The correlation analysis of in vitro and in vivo activities revealed that the observed 648 
antimycobacterial effect is not exclusively originates from MtTMPK inhibition, hence further 649 
target validation is required in case of these compounds. The same holds for inhibitors 650 
developed against the PfTMPK, which exhibit promising antimalarial activity and selectivity 651 
between P. falciparum and human enzymes, but the mechanism of in vivo action is yet 652 
equivocal [233]. To best of our knowledge, no report is yet available on Leishmanial TMPKs, 653 
also in the case of B. anthracis TMPK only a preliminary study has been reported to date 654 
[234].   655 
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5. New waves: proteinaceous inhibition of dUTPase and UNG  656 
Recently a Staphylococcal protein (Stl) has been identified as a competitive inhibitor of a 657 
phage related dUTPase with nanomolar inhibitory constant [235–237]. It has also been shown 658 
that the inhibition is independent from the phage specific insert and Stl binds and inhibits 659 
Mycobacterial dUTPases in vitro and in vivo [238,239]. These developments shed light on the 660 
possibility of using protein inhibitors to target enzymes in the thymidylate biosynthesis 661 
pathway. Proteinaceous inhibition and the use of proteins as drugs have several advantages 662 
and disadvantages, as well. Among the positive factors, it should be mentioned first of all, that 663 
macromolecular inhibition may offer unprecedented specificity, and can also be tailored using 664 
site-specific mutations to target dUTPases from different species. However, the use of 665 
proteins as drugs may imply many technical difficulties, among which the question how we 666 
can achieve an effective concentration of the macromolecular inhibitor in the vicinity of the 667 
target protein remains to be elusive. Still, despite all technical difficulties, macromolecular 668 
drugs are up coming and it can be expected that such approaches will prove to be successful 669 
in the next few years. 670 
Another proteinaceous inhibitor within the DNA damage and repair pathways is the uracil-671 
DNA glycosylase inhibitor Ugi. A recent study suggests that depletion of the uracil DNA 672 
glycosylase (UNG) sensitizes tumor cells to FdUrd, because of activation more error prone 673 
DNA repair mechanisms against the incorporated 5F-uracil [236]. We propose that the 674 
potential significance of a proteinaceous inhibitor against UNG can be tested in pathogens, as 675 
well. In this regard a pioneering study on the recently discovered Ugi protein from 676 
Staphylococcus aureus attempts to modulate the inhibitor ability of this protein against human 677 
herpesvirus UDG [240,241]. Based on the promising results of these first experiments, the 678 
Ugi inhibitor may serve as a new type of drug candidate molecule. 679 
Conclusions 680 
We have reviewed the current state of using drugs against thymidylate biosynthesis to fight 681 
pathogenic microorganisms. Some major general aspects may be emphasized in these efforts. 682 
Since in many cases, e.g. with dUTPases and thymidylate synthases, the target pathogen 683 
enzyme has a closely-related human homologue as well, the problem of selectivity has to be 684 
addressed. This can be approached in two ways: on the one hand, the designed drug candidate 685 
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may possess chemical moieties that enhance selectivity [13], whereas on the other hand, the 686 
targeted enzyme surface needs to include species-specific segments [15].  687 
In more convenient scenarios, the target enzyme in the pathogenic microorganisms possesses 688 
either somewhat altered three-dimensional structure or completely different protein fold, 689 
allowing a more straightforward approach for pathogen species-specific drug design. 690 
Examples in these cases include e.g the Plasmodium dUTPase where one protein segment 691 
shows a distinct conformation as compared to human dUTPase, as well as the dUTPases from 692 
Trypanosomes and Leishmania species, which are representatives of the all-α dimeric 693 
dUTPase family possessing also an altered mechanism of action as compared to the more 694 
general all-β trimeric dUTPases. In the family of thymidylate synthases, some pathogens, like 695 
Mycobacterium tuberculosis and Helicobacter pylori, luckily encode this enzymatic activity 696 
in a protein (nick-named as ThyX) that is fully divergent from its human counterpart. 697 
Further, to overcome the mechanisms of development of resistance, the novel drug candidates 698 
need to possess new mechanisms of action. It is also a promising concept to apply 699 
combination therapies by simultaneous application of drug candidates targeting different 700 
enzymes. Finally, during the fine-tuning of drug-like compounds, the key properties that are 701 
significant for drug action (eg solubility, penetration properties, specificity, toxicity) should 702 
be optimized in parallel to each other. 703 
 704 
Acknowledgements 705 
Authors thank for the support of Hungarian Scientific Research Fund OTKA [NK 84008, 706 
K109486]; Baross Program of the New Hungary Development Plan [3DSTRUCT, OMFB-707 
00266/2010 REG-KM- 09-1-2009-0050]; Hungarian Academy of Sciences ([TTK IF-28/ 708 
2012]; MedinProt program); the ICGEB Research Grant to BGV (CRP/HUN14-01) and the 709 
European Commission FP7 Biostruct-X project [contract No. 283570]. Funding for open 710 
access charge: Hungarian Academy of Sciences.  711 
  712 
Author manuscript published in: BBA - General Subjects 
45 
References 713 
[1] H.I.M. Boshoff, M.B. Reed, C.E. Barry, V. Mizrahi, DnaE2 polymerase contributes to 714 
in vivo survival and the emergence of drug resistance in Mycobacterium tuberculosis, 715 
Cell, 113 (2003) 183–193. 716 
[2] A.C. Anderson, D.L. Wright, Antifolate agents: a patent review (2006-2010), Expert 717 
Opin. Ther. Pat., 21 (2011) 1293–1308. 718 
[3] A.C. Anderson, D.L. Wright, Antifolate agents: a patent review (2010-2013), Expert 719 
Opin. Ther. Pat., 24 (2014) 687–697. 720 
[4] B.G. Vértessy, J. Tóth, Keeping uracil out of DNA: physiological role, structure and 721 
catalytic mechanism of dUTPases, Acc. Chem. Res., 42 (2009) 97–106. 722 
[5] G.N. Nagy, I. Leveles, B.G. Vértessy, Preventive DNA repair by sanitizing the cellular 723 
(deoxy)nucleoside triphosphate pool, FEBS J., 281 (2014) 4207–23. 724 
[6] V.M. Castillo-Acosta, A.M. Estévez, A.E. Vidal, L.M. Ruiz-Perez, D. González-725 
Pacanowska, Depletion of dimeric all-alpha dUTPase induces DNA strand breaks and 726 
impairs cell cycle progression in Trypanosoma brucei, Int. J. Biochem. Cell Biol., 40 727 
(2008) 2901–13. 728 
[7] G.R. Hemsworth, O. V Moroz, M.J. Fogg, B. Scott, C. Bosch-Navarrete, D. González-729 
Pacanowska, K.S. Wilson, The crystal structure of the Leishmania major deoxyuridine 730 
triphosphate nucleotidohydrolase in complex with nucleotide analogues, dUMP, and 731 
deoxyuridine, J. Biol. Chem., 286 (2011) 16470–81. 732 
[8] M. Harkiolaki, E.J. Dodson, V. Bernier-Villamor, J.P. Turkenburg, D. González-733 
Pacanowska, K.S. Wilson, The crystal structure of Trypanosoma cruzi dUTPase 734 
reveals a novel dUTP/dUDP binding fold, Structure, 12 (2004) 41–53. 735 
[9] O. V Moroz, M. Harkiolaki, M.Y. Galperin, A.A. Vagin, D. González-Pacanowska, 736 
K.S. Wilson, The crystal structure of a complex of Campylobacter jejuni dUTPase with 737 
substrate analogue sheds light on the mechanism and suggests the “basic module” for 738 
dimeric d(C/U)TPases, J. Mol. Biol., 342 (2004) 1583–97. 739 
[10] O.K. Mc Carthy, A. Schipani, A.M. Buendía, L.M. Ruiz-Perez, M. Kaiser, R. Brun, 740 
D.G. Pacanowska, I.H. Gilbert, Design, synthesis and evaluation of novel uracil amino 741 
acid conjugates for the inhibition of Trypanosoma cruzi dUTPase, Bioorg. Med. Chem. 742 
Lett., 16 (2006) 3809–3812. 743 
[11] H. Saito, H. Tomioka, Thymidine kinase of bacteria: activity of the enzyme in 744 
actinomycetes and related organisms, J. Gen. Microbiol., 130 (1984) 1863–70. 745 
[12] S. Chan, B. Segelke, T. Lekin, H. Krupka, U.S. Cho, M.-Y. Kim, M. So, C.-Y. Kim, 746 
C.M. Naranjo, Y.C. Rogers, M.S. Park, G.S. Waldo, I. Pashkov, D. Cascio, J.L. Perry, 747 
M.R. Sawaya, Crystal structure of the Mycobacterium tuberculosis dUTPase: insights 748 
into the catalytic mechanism, J. Mol. Biol., 341 (2004) 503–17. 749 
[13] J.L. Whittingham, I. Leal, C. Nguyen, G. Kasinathan, E. Bell, A.F. Jones, C. Berry, A. 750 
Benito, J.P. Turkenburg, E.J. Dodson, L.M. Ruiz Perez, A.J. Wilkinson, N.G. 751 
Johansson, R. Brun, I.H. Gilbert, D. Gonzalez Pacanowska, K.S. Wilson, dUTPase as a 752 
Author manuscript published in: BBA - General Subjects 
46 
platform for antimalarial drug design: structural basis for the selectivity of a class of 753 
nucleoside inhibitors, Structure, 13 (2005) 329–38. 754 
[14] B. Varga, O. Barabás, E. Takács, N. Nagy, P. Nagy, B.G. Vértessy, Active site of 755 
mycobacterial dUTPase: structural characteristics and a built-in sensor, Biochem. 756 
Biophys. Res. Commun., 373 (2008) 8–13. 757 
[15] K. Horváti, B. Bacsa, N. Szabó, K. Fodor, G. Balka, M. Rusvai, É. Kiss, G. Mező, V. 758 
Grolmusz, B. Vértessy, F. Hudecz, S. Bősze, Antimycobacterial activity of peptide 759 
conjugate of pyridopyrimidine derivative against Mycobacterium tuberculosis in a 760 
series of in vitro and in vivo models, Tuberculosis, 95 (2015) 207–211. 761 
[16] J.J. Irwin, B.K. Shoichet, ZINC − A Free Database of Commercially Available 762 
Compounds for Virtual Screening ZINC - A Free Database of Commercially Available 763 
Compounds for Virtual Screening, J. Chem. Inf. Model, 45 (2005) 177–182. 764 
[17] I. Pecsi, R. Hirmondo, A.C. Brown, A. Lopata, T. Parish, B.G. Vertessy, J. Tóth, The 765 
dUTPase enzyme is essential in Mycobacterium smegmatis, PLoS One, 7 (2012) 766 
e37461. 767 
[18] G.J. Crowther, A.J. Napuli, J.H. Gilligan, K. Gagaring, R. Borboa, C. Francek, Z. 768 
Chen, E.F. Dagostino, J.B. Stockmyer, Y. Wang, P.P. Rodenbough, L.J. Castaneda, 769 
D.J. Leibly, J. Bhandari, M.H. Gelb, A. Brinker, I.H. Engels, J. Taylor, A.K. 770 
Chatterjee, P. Fantauzzi, et al., Identification of inhibitors for putative malaria drug 771 
targets among novel antimalarial compounds, Mol. Biochem. Parasitol., 175 (2011) 772 
21–29. 773 
[19] E. Recio, A. Musso-Buendía, A.E. Vidal, G.F. Ruda, G. Kasinathan, C. Nguyen, L.M. 774 
Ruiz-Pérez, I.H. Gilbert, D. González-Pacanowska, Site-directed mutagenesis provides 775 
insights into the selective binding of trityl derivatives to Plasmodium falciparum 776 
dUTPase, Eur. J. Med. Chem., 46 (2011) 3309–14. 777 
[20] B. Baragaña, O. McCarthy, P. Sánchez, C. Bosch-Navarrete, M. Kaiser, R. Brun, J.L. 778 
Whittingham, S.M. Roberts, X.X. Zhou, K.S. Wilson, N.G. Johansson, D. González-779 
Pacanowska, I.H. Gilbert, β-Branched acyclic nucleoside analogues as inhibitors of 780 
Plasmodium falciparum dUTPase, Bioorganic Med. Chem., 19 (2011) 2378–2391. 781 
[21] R. de Araújo Santos, C. Braz, J. Ghasemi, R. Safavi-Sohi, E. Barbosa, Mixed 2D–3D-782 
LQTA-QSAR study of a series of Plasmodium falciparum dUTPase inhibitors, Med. 783 
Chem. Res., 24 (2015) 1098–1111. 784 
[22] A. Camacho, R. Arrebola, J. Pena-Diaz, L.M. Ruiz-Perez, D. Gonzalez-Pacanowska, 785 
Description of a novel eukaryotic deoxyuridine 5’-triphosphate nucleotidohydrolase in 786 
Leishmania major, Biochem J, 325 (1997) 441–447. 787 
[23] A. Camacho, F. Hidalgo-Zarco, V. Bernier-Villamor, L.M. Ruiz-Pérez, D. González-788 
Pacanowska, Properties of Leishmania major dUTP nucleotidohydrolase, a distinct 789 
nucleotide-hydrolysing enzyme in kinetoplastids, Biochem. J., 346 Pt 1 (2000) 163–790 
168. 791 
[24] F. Hidalgo-Zarco, A.G. Camacho, V. Bernier-Villamor, J. Nord, L.M. Ruiz-Pérez, D. 792 
González-Pacanowska, Kinetic properties and inhibition of the dimeric dUTPase-793 
dUDPase from Leishmania major, Protein Sci., 10 (2001) 1426–1433. 794 
Author manuscript published in: BBA - General Subjects 
47 
[25] V.M. Castillo-Acosta, F. Aguilar-Pereyra, D. García-Caballero, A.E. Vidal, L.M. Ruiz-795 
Pérez, D. González-Pacanowska, Pyrimidine requirements in deoxyuridine 796 
triphosphate nucleotidohydrolase deficient Trypanosoma brucei mutants, Mol. 797 
Biochem. Parasitol., 187 (2013) 9–13. 798 
[26] G.R. Hemsworth, D. González-Pacanowska, K.S. Wilson, On the catalytic mechanism 799 
of dimeric dUTPases, Biochem. J., 456 (2013) 81–8. 800 
[27] J.A. Musso-Buendía, A.E. Vidal, G. Kasinthan, C. Nguyen, J. Carrero-Lérida, L.M. 801 
Ruiz-Pérez, K. Wilson, N.G. Johansson, I.H. Gilbert, D. González-Pacanowska, 802 
Kinetic properties and inhibition of the dimeric dUTPase-dUDPase from 803 
Campylobacter jejuni, J. Enzyme Inhib. Med. Chem., 24 (2009) 111–116. 804 
[28] S.S. Helt, M. Thymark, P. Harris, C. Aagaard, J. Dietrich, S. Larsen, M. Willemoes, 805 
Mechanism of dTTP inhibition of the bifunctional dCTP deaminase:dUTPase encoded 806 
by Mycobacterium tuberculosis, J. Mol. Biol., 376 (2008) 554–69. 807 
[29] T.C. Ramalho, M.S. Caetano, D. Josa, G.P. Luz, E.A. Freitas, E.F.F. da Cunha, 808 
Molecular modeling of Mycobacterium tuberculosis dUTpase: docking and catalytic 809 
mechanism studies, J. Biomol. Struct. Dyn., 28 (2011) 907–17. 810 
[30] R. Hirmondo, A. Lopata, É. Böttger, B.G. Vertessy, J. Tóth, Differential control of 811 
dNTP biosynthesis and genome integrity maintenance by dUTPases, Sci. Rep., (2016) 812 
under review. 813 
[31] C. Nguyen, G. Kasinathan, I. Leal-Cortijo, A. Musso-Buendia, M. Kaiser, R. Brun, 814 
L.M. Ruiz-Pérez, N.G. Johansson, D. González-Pacanowska, I.H. Gilbert, 815 
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target, 816 
J. Med. Chem., 48 (2005) 5942–5954. 817 
[32] C. Nguyen, G.F. Ruda, A. Schipani, G. Kasinathan, I. Leal, A. Musso-Buendia, M. 818 
Kaiser, R. Brun, L.M. Ruiz-Perez, B.-L. Sahlberg, N.G. Johansson, D. Gonzalez-819 
Pacanowska, I.H. Gilbert, Acyclic Nucleoside Analogues as Inhibitors of Plasmodium 820 
falciparum dUTPase, J. Med. Chem., 49 (2006) 4183–4195. 821 
[33] I. Quesada-Soriano, J.A. Musso-Buendia, R. Tellez-Sanz, L.M. Ruíz-pérez, C. Barón, 822 
D. González-Pacanowska, L. García-Fuentes, Plasmodium falciparum dUTPase: 823 
studies on protein stability and binding of deoxyuridine derivatives, Biochim. Biophys. 824 
Acta, 1774 (2007) 936–45. 825 
[34] O. McCarthy, A. Musso-Buendia, M. Kaiser, R. Brun, L.M. Ruiz-Perez, N.G. 826 
Johansson, D.G. Pacanowska, I.H. Gilbert, Design, synthesis and evaluation of novel 827 
uracil acetamide derivatives as potential inhibitors of Plasmodium falciparum dUTP 828 
nucleotidohydrolase, Eur. J. Med. Chem., 44 (2009) 678–688. 829 
[35] L. García-fuentes, A. Vargas-berenguel, D. Gonz, I. Quesada-Soriano, J.M. Casas-830 
Solvas, E. Recio, L.M. Ruiz-Pérez, D. González-Pacanowska, A. Vargas-berenguel, D. 831 
González-Pacanowska, L. García-fuentes, D. Gonz, A. Vargas-berenguel, D. Gonz, I. 832 
Quesada-Soriano, J.M. Casas-Solvas, E. Recio, L.M. Ruiz-Pérez, D. González-833 
Pacanowska, A. Vargas-berenguel, et al., Kinetic properties and specificity of trimeric 834 
Plasmodium falciparum and human dUTPases, Biochimie, 92 (2010) 178–86. 835 
[36] G.F. Ruda, C. Nguyen, P. Ziemkowski, K. Felczak, G. Kasinathan, A. Musso-Buendia, 836 
Author manuscript published in: BBA - General Subjects 
48 
C. Sund, X.X. Zhou, M. Kaiser, L.M. Ruiz-Pérez, R. Brun, T. Kulikowski, N.G. 837 
Johansson, D. González-Pacanowska, I.H. Gilbert, Modified 5’-trityl nucleosides as 838 
inhibitors of Plasmodium falciparum dUTPase, ChemMedChem, 6 (2011) 309–20. 839 
[37] S.E. Hampton, B. Baragaña, A. Schipani, C. Bosch-Navarrete, J.A. Musso-Buendía, E. 840 
Recio, M. Kaiser, J.L. Whittingham, S.M. Roberts, M. Shevtsov, J. Brannigan, P. 841 
Kahnberg, R. Brun, K.S. Wilson, D. González-Pacanowska, N.G. Johansson, I.H. 842 
Gilbert, Design, Synthesis, and Evaluation of 5′-Diphenyl Nucleoside Analogues as 843 
Inhibitors of the Plasmodium falciparum dUTPase, ChemMedChem, 6 (2011) 1816–844 
1831. 845 
[38] S.E. Hampton, A. Schipani, C. Bosch-Navarrete, E. Recio, M. Kaiser, P. Kahnberg, D. 846 
González-Pacanowska, N.G. Johansson, I.H. Gilbert, Investigation of acyclic uridine 847 
amide and 5′-amido nucleoside analogues as potential inhibitors of the Plasmodium 848 
falciparum dUTPase, Bioorganic Med. Chem., 21 (2013) 5876–5885. 849 
[39] T. V Mishanina, L. Yu, K. Karunaratne, D. Mondal, An unprecedented mechanism of 850 
nucleotide methylation in organisms containing thyX, Science., 351 (2016) 507–510. 851 
[40] V.P. Kumar, J.A. Cisneros, K.M. Frey, A. Castellanos-Gonzalez, Y. Wang, A. 852 
Gangjee, A.C. White, W.L. Jorgensen, K.S. Anderson, Structural studies provide clues 853 
for analog design of specific inhibitors of Cryptosporidium hominis thymidylate 854 
synthase-dihydrofolate reductase, Bioorg. Med. Chem. Lett., 24 (2014) 4158–61. 855 
[41] S. Ferrari, P.M. Costi, R.C. Wade, Inhibitor specificity via protein dynamics: insights 856 
from the design of antibacterial agents targeted against thymidylate synthase, Chem. 857 
Biol., 10 (2003) 1183–1193. 858 
[42] C.W. Carreras, D. V. Santi, The catalytic mechanism and structure of thymidylate 859 
synthase, Annu. Rev. Biochem., 64 (1995) 721–762. 860 
[43] D. Tondi, A. Venturelli, S. Ferrari, S. Ghelli, M.P. Costi, Improving specificity vs 861 
bacterial thymidylate synthases through N-dansyl modulation of didansyltyrosine, J. 862 
Med. Chem., 48 (2005) 913–916. 863 
[44] S. Ferrari, V. Losasso, M.P. Costi, Sequence-based identification of specific drug target 864 
regions in the thymidylate synthase enzyme family, ChemMedChem, 3 (2008) 392–865 
401. 866 
[45] B.K. Shoichet, R.M. Stroud, D. V Santi, I.D. Kuntz, K.M. Perry, Structure-based 867 
discovery of inhibitors of thymidylate synthase, Science., 259 (1993) 1445–1450. 868 
[46] J. Finer-Moore, E.B. Fauman, P.G. Foster, K.M. Perry, D. V. Santi, R.M. Stroud, 869 
Refined Structures of Substrate-bound and Phosphate-bound Thymidylate Synthase 870 
from Lactobacillus casei, J. Mol. Biol., 232 (1993) 1101–1116. 871 
[47] A.C. Anderson, K.M. Perry, D.M. Freymann, R.M. Stroud, The crystal structure of 872 
thymidylate synthase from Pneumocystis carinii reveals a fungal insert important for 873 
drug design, J.Mol.Biol., 297 (2000) 645–657. 874 
[48] T.J. Stout, D. Tondi, M. Rinaldi, D. Barlocco, P. Pecorari, D. V. Santi, I.D. Kuntz, 875 
R.M. Stroud, B.K. Shoichet, M.P. Costi, Structure-based design of inhibitors specific 876 
for bacterial thymidylate synthase, Biochemistry, 38 (1999) 1607–1617. 877 
Author manuscript published in: BBA - General Subjects 
49 
[49] P.M. Costi, M. Rinaldi, D. Tondi, P. Pecorari, D. Barlocco, S. Ghelli, R.M. Stroud, D. 878 
V Santi, T.J. Stout, C. Musiu, E.M. Marangiu, A. Pani, D. Congiu, G.A. Loi, P. La 879 
Colla, Phthalein derivatives as a new tool for selectivity in thymidylate synthase 880 
inhibition, J. Med. Chem., 42 (1999) 2112–2124. 881 
[50] J.S. Finer-Moore, A.C. Anderson, R.H. O’Neil, M.P. Costi, S. Ferrari, J. Krucinski, 882 
R.M. Stroud, The structure of Cryptococcus neoformans thymidylate synthase suggests 883 
strategies for using target dynamics for species-specific inhibition, Acta Crystallogr. 884 
Sect. D Biol. Crystallogr., 61 (2005) 1320–1334. 885 
[51] D. Tondi, U. Slomczynska, M.P. Costi, D.M. Watterson, S. Ghelli, B.K. Shoichet, 886 
Structure-based discovery and in-parallel optimization of novelcompetitive inhibitors 887 
of thymidylate synthase, Chem. Biol., 6 (1999) 319–31. 888 
[52] T.A. Fritz, D. Tondi, J.S. Finer-Moore, M.P. Costi, R.M. Stroud, Predicting and 889 
harnessing protein flexibility in the design of species-specific inhibitors of thymidylate 890 
synthase, Chem. Biol., 8 (2001) 981–995. 891 
[53] M.P. Costi, A. Gelain, D. Barlocco, S. Ghelli, F. Soragni, F. Reniero, T. Rossi, A. 892 
Ruberto, C. Guillou, A. Cavazzuti, C. Casolari, S. Ferrari, Antibacterial agent 893 
discovery using thymidylate synthase biolibrary screening, J. Med. Chem., 49 (2006) 894 
5958–5968. 895 
[54] S. Mangani, L. Cancian, R. Leone, C. Pozzi, S. Lazzari, R. Luciani, S. Ferrari, M.P. 896 
Costi, Identification of the binding modes of N-phenylphthalimides inhibiting bacterial 897 
thymidylate synthase through X-ray crystallography screening, J. Med. Chem., 54 898 
(2011) 5454–5467. 899 
[55] S. Ferrari, M. Ingrami, F. Soragni, R.C. Wade, M.P. Costi, Ligand-based discovery of 900 
N-(1,3-dioxo-1H,3H-benzo[de]isochromen-5-yl)-carboxamide and sulfonamide 901 
derivatives as thymidylate synthase A inhibitors, Bioorg. Med. Chem. Lett., 23 (2013) 902 
663–668. 903 
[56] S. Ferrari, S. Calo, R. Leone, R. Luciani, L. Costantino, S. Sammak, F. Di Pisa, C. 904 
Pozzi, S. Mangani, M.P. Costi, 2′-Deoxyuridine 5′-Monophosphate Substrate 905 
Displacement in Thymidylate Synthase through 6‑Hydroxy‑2H‑naphtho[1,8-bc]furan- 906 
2-one Derivatives, J. Med. Chem., 56 (2013) 9356−9360. 907 
[57] C. Pozzi, S. Ferrari, D. Cortesi, R. Luciani, R.M. Stroud, A. Catalano, M.P. Costi, S. 908 
Mangani, The structure of Enterococcus faecalis thymidylate synthase provides clues 909 
about folate bacterial metabolism, Acta Crystallogr. Sect. D Biol. Crystallogr., 68 910 
(2012) 1232–1241. 911 
[58] S. Calò, D. Tondi, S. Ferrari, A. Venturelli, S. Ghelli, M.P. Costi, Constrained Dansyl 912 
Derivatives Reveal Bacterial Specificity of Highly Conserved Thymidylate Synthases, 913 
ChemBioChem, 9 (2008) 779–790. 914 
[59] H. Myllykallio, G. Lipowski, D. Leduc, J. Filee, P. Forterre, U. Liebl, An Alternative 915 
Flavin-Dependent Mechanism for Thymidylate Synthesis, Science (80-. )., 297 (2002) 916 
105–107. 917 
[60] D. Leduc, S. Graziani, G. Lipowski, C. Marchand, P. Le Maréchal, U. Liebl, H. 918 
Myllykallio, Functional evidence for active site location of tetrameric thymidylate 919 
Author manuscript published in: BBA - General Subjects 
50 
synthase X at the interphase of three monomers, Proc. Natl. Acad. Sci. U. S. A., 101 920 
(2004) 7252–7. 921 
[61] D. Leduc, F. Escartin, H.F. Nijhout, M.C. Reed, U. Liebl, S. Skouloubris, H. 922 
Myllykallio, Flavin-dependent thymidylate synthase ThyX activity: Implications for 923 
the folate cycle in bacteria, J. Bacteriol., 189 (2007) 8537–8545. 924 
[62] I.I. Mathews, A.M. Deacon, J.M. Canaves, D. McMullan, S. Lesley, S. Agarwalla, P. 925 
Kuhn, Functional analysis of substrate and cofactor complex structures of a 926 
thymidylate synthase-complementing protein, Structure, 11 (2003) 677–690. 927 
[63] S. Graziani, Y. Xia, J.R. Gurnon, J.L. Van Etten, D. Leduc, S. Skouloubris, H. 928 
Myllykallio, U. Liebl, Functional analysis of FAD-dependent thymidylate synthase 929 
ThyX from Paramecium bursaria chlorella virus-1, J. Biol. Chem., 279 (2004) 54340–930 
54347. 931 
[64] J.H. Hunter, R. Gujjar, C.K.T. Pang, P.K. Rathod, Kinetics and ligand-binding 932 
preferences of Mycobacterium tuberculosis thymidylate synthases, ThyA and ThyX, 933 
PLoS One, 3 (2008) 1–10. 934 
[65] E.M. Koehn, T. Fleischmann, J.A. Conrad, B.A. Palfey, S.A. Lesley, I.I. Mathews, A. 935 
Kohen, An unusual mechanism of thymidylate biosynthesis in organisms containing 936 
the thyX gene, Nature, 458 (2009) 919–923. 937 
[66] A. Chernyshev, T. Fleischmann, A. Kohen, Thymidyl biosynthesis enzymes as 938 
antibiotic targets, Appl. Microbiol. Biotechnol., 74 (2007) 282–9. 939 
[67] J. Rengarajan, C.M. Sassetti, V. Naroditskaya, A. Sloutsky, B.R. Bloom, E.J. Rubin, 940 
The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) 941 
in mycobacteria, Mol. Microbiol., 53 (2004) 275–282. 942 
[68] A.S. Fivian-Hughes, J. Houghton, E.O. Davis, Mycobacterium tuberculosis 943 
thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA 944 
deletion confers resistance to p-aminosalicylic acid, Microbiology, 158 (2012) 308–18. 945 
[69] P. Sampathkumar, S. Turley, J.E. Ulmer, H.G. Rhie, C.H. Sibley, W.G.J. Hol, 946 
Structure of the Mycobacterium tuberculosis flavin dependent thymidylate synthase 947 
(MtbThyX) at 2,0 A resolution, J. Mol. Biol., 352 (2005) 1091–1104. 948 
[70] P. Sampathkumar, S. Turley, C.H. Sibley, W.G.J. Hol, NADP+ expels both the co-949 
factor and a substrate analog from the Mycobacterium tuberculosis ThyX active site: 950 
opportunities for anti-bacterial drug design, J. Mol. Biol., 360 (2006) 1–6. 951 
[71] K. Wang, Q. Wang, J. Chen, L. Chen, H. Jiang, X. Shen, Crystal structure and 952 
enzymatic characterization of thymidylate synthase X from Helicobacter pylori strain 953 
SS1, Protein Sci., 20 (2011) 1398–1410. 954 
[72] X. Zhang, J. Zhang, G. Guo, X. Mao, Y. Hu, Q. Zou, Crystal structure of a flavin-955 
dependent thymidylate synthase from helicobacter pylori strain 26695, Protein Pept. 956 
Lett., 19 (2012) 1225–1230. 957 
[73] E.M. Koehn, L.L. Perissinotti, S. Moghram, A. Prabhakar, S. Lesley, I.I. Mathews, A. 958 
Kohen, Folate binding site of flavin-dependent thymidylate synthase, Proc. Natl. Acad. 959 
Sci., 109 (2012) 15722–15727. 960 
Author manuscript published in: BBA - General Subjects 
51 
[74] I.I. Mathews, Flavin-Dependent Thymidylate Synthase as a Drug Target for Deadly 961 
Microbes: Mutational Study and a Strategy for Inhibitor Design, J. Bioterror. Biodef., 962 
Suppl 12 (2013) 004. 963 
[75] L. Baugh, I. Phan, D.W. Begley, M.C. Clifton, B. Armour, D.M. Dranow, B.M. Taylor, 964 
M.M. Muruthi, J. Abendroth, J.W. Fairman, D.F. III, S.H. Dieterich, B.L. Staker, A.S. 965 
Gardberg, R. Choi, S.N. Hewitt, A.J. Napuli, J. Myers, L.K. Barrett, Y. Zhang, et al., 966 
Increasing the structural coverage of tuberculosis drug targets, Tuberculosis, 95 (2015) 967 
142–148. 968 
[76] M. Kögler, B. Vanderhoydonck, S. De Jonghe, J. Rozenski, K. Van Belle, J. Herman, 969 
T. Louat, A. Parchina, C. Sibley, E. Lescrinier, P. Herdewijn, Synthesis and evaluation 970 
of 5-substituted 2′-deoxyuridine monophosphate analogues as inhibitors of flavin-971 
dependent thymidylate synthase in mycobacterium tuberculosis, J. Med. Chem., 54 972 
(2011) 4847–4862. 973 
[77] M. Kögler, R. Busson, S. De Jonghe, J. Rozenski, K. Van Belle, T. Louat, H. Munier-974 
Lehmann, P. Herdewijn, Synthesis and evaluation of 6-Aza-2′-deoxyuridine 975 
monophosphate analogs as inhibitors of thymidylate synthases, and as substrates or 976 
inhibitors of thymidine monophosphate kinase in mycobacterium tuberculosis, Chem. 977 
Biodivers., 9 (2012) 536–556. 978 
[78] A. Parchina, M. Froeyen, L. Margamuljana, J. Rozenski, S. DeJonghe, Y. Briers, R. 979 
Lavigne, P. Herdewijn, E. Lescrinier, Discovery of an acyclic nucleoside phosphonate 980 
that inhibits mycobacterium tuberculosis ThyX based on the binding mode of a 5-981 
Alkynyl substrate analogue, ChemMedChem, 8 (2013) 1373–1383. 982 
[79] L.A. Alexandrova, V.O. Chekhov, E.R. Shmalenyuk, S.N. Kochetkov, R.A. El-Asrar, 983 
P. Herdewijn, Synthesis and evaluation of C-5 modified 2′-deoxyuridine 984 
monophosphates as inhibitors of M tuberculosis thymidylate synthase, Bioorg. Med. 985 
Chem., 23 (2015) 7131–7137. 986 
[80] E.R. Shmalenyuk, S.N. Kochetkov, L.A. Alexandrova, Novel inhibitors of 987 
Mycobacterium tuberculosis growth based on modified pyrimidine nucleosides and 988 
their analogues, Russ. Chem. Rev., 82 (2013) 896–915. 989 
[81] S. Graziani, J. Bernauer, S. Skouloubris, M. Graille, C.Z. Zhou, C. Marchand, P. 990 
Decottignies, H. Van Tilbeurgh, H. Myllykallio, U. Liebl, Catalytic mechanism and 991 
structure of viral flavin-dependent thymidylate synthase ThyX, J. Biol. Chem., 281 992 
(2006) 24048–24057. 993 
[82] F. Esra Önen, Y. Boum, C. Jacquement, M.V. Spanedda, N. Jaber, D. Scherman, H. 994 
Myllykallio, J. Herscovici, Design, synthesis and evaluation of potent thymidylate 995 
synthase X inhibitors, Bioorganic Med. Chem. Lett., 18 (2008) 3628–3631. 996 
[83] T. Basta, Y. Boum, J. Briffotaux, H.F. Becker, I. Lamarre-Jouenne, J.-C. Lambry, S. 997 
Skouloubris, U. Liebl, M. Graille, H. van Tilbeurgh, H. Myllykallio, Mechanistic and 998 
structural basis for inhibition of thymidylate synthase ThyX, Open Biol., 2 (2012) 999 
120120–120120. 1000 
[84] K. Djaout, I. Lamarre, J. Lambry, K. Anger, J. Briffotaux, U. Liebl, H. De Reuse, H. 1001 
Myllykallio, Targeting of Helicobacter pylori thymidylate synthase ThyX by non- 1002 
mitotoxic hydroxy-naphthoquinones, Open Biol., 5 (2015) 150015. 1003 
Author manuscript published in: BBA - General Subjects 
52 
[85] H.F. Becker, K. Djaout, I. Lamarre, J.E. Ulmer, D. Schaming, V. Balland, U. Liebl, H. 1004 
Myllykallio, M.H. Vos, Substrate interaction dynamics and oxygen control in the active 1005 
site of thymidylate synthase ThyX, Biochem. J., 459 (2014) 37–45. 1006 
[86] J.E. Ulmer, Y. Boum, C.D. Thouvenel, H. Myllykallio, C.H. Sibley, Functional 1007 
analysis of the Mycobacterium tuberculosis FAD-dependent thymidylate synthase, 1008 
ThyX, reveals new amino acid residues contributing to an extended ThyX motif, J. 1009 
Bacteriol., 190 (2008) 2056–2064. 1010 
[87] V. Singh, M. Brecik, R. Mukherjee, J.C. Evans, Z. Svetlíková, J. Blaško, S. Surade, J. 1011 
Blackburn, D.F. Warner, K. Mikušová, V. Mizrahi, The complex mechanism of 1012 
antimycobacterial action of 5-Fluorouracil, Chem. Biol., 22 (2015) 63–75. 1013 
[88] V.H. Vestereng, J.A. Kovacs, Inability of Pneumocystis organisms to incorporate 1014 
bromodeoxyuridine suggests the absence of a salvage pathway for thymidine, 1015 
Microbiology, 150 (2004) 1179–1182. 1016 
[89] J.N. Champness, A. Achari, S.P. Ballantine, P.K. Bryant, C.J. Delves, D.K. Stammers, 1017 
The structure of Pneumocystis carinii dihydrofolate reductase to 1,9 A resolution, 1018 
Struct. London Engl. 1993, 2 (1994) 915–924. 1019 
[90] A. Gangjee, A. Vasudevan, S.F. Queener, R.L. Kisliuk, 2,4-Diamino-5-deaza-6-1020 
substituted pyrido[2,3-d]pyrimidine antifolates as potent and selective nonclassical 1021 
inhibitors of dihydrofolate reductases, J. Med. Chem., 39 (1996) 1438–1446. 1022 
[91] V. Cody, J. Pace, O.A. Namjoshi, A. Gangjee, Structure–activity correlations for three 1023 
pyrido[2,3- d ]pyrimidine antifolates binding to human and Pneumocystis carinii 1024 
dihydrofolate reductase, Acta Crystallogr. Sect. F Struct. Biol. Commun., 71 (2015) 1025 
799–803. 1026 
[92] A. Gangjee, O.A. Namjoshi, S. Raghavan, S.F. Queener, R.L. Kisliuk, V. Cody, 1027 
Design, synthesis, and molecular modeling of novel pyrido[2,3-d]pyrimidine analogues 1028 
as antifolates; Application of buchwald-hartwig aminations of heterocycles, J. Med. 1029 
Chem., 56 (2013) 4422–4441. 1030 
[93] A. Gangjee, A.P. Vidwans, A. Vasudevan, S.F. Queener, R.L. Kisliuk, V. Cody, R. Li, 1031 
N. Galitsky, J.R. Luft, W. Pangborn, Structure-based design and synthesis of lipophilic 1032 
2,4-diamino-6- substituted quinazolines and their evaluation as inhibitors of 1033 
dihydrofolate reductases and potential antitumor agents, J. Med. Chem., 41 (1998) 1034 
3426–3434. 1035 
[94] A. Gangjee, O.O. Adair, M. Pagley, S.F. Queener, N9-Substituted 2,4-1036 
Diaminoquinazolines: Synthesis and Biological Evaluation of Lipophilic Inhibitors of 1037 
Pneumocystis carinii and Toxoplasma gondii Dihydrofolate Reductase, J. Med. Chem., 1038 
51 (2008) 6195–6200. 1039 
[95] A. Gangjee, H.D. Jain, J. Phan, X. Guo, S.F. Queener, R.L. Kisliuk, 2,4-Diamino-5-1040 
methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and 1041 
nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate 1042 
reductase inhibitors, Bioorg. Med. Chem., 18 (2010) 953–61. 1043 
[96] E.W. Barrow, P.C. Bourne, W.W. Barrow, Functional Cloning of Bacillus anthracis 1044 
Dihydrofolate Reductase and Confirmation of Natural Resistance to Trimethoprim 1045 
Author manuscript published in: BBA - General Subjects 
53 
Functional Cloning of Bacillus anthracis Dihydrofolate Reductase and Confirmation of 1046 
Natural Resistance to Trimethoprim, 48 (2004) 4643–4649. 1047 
[97] T.M. Joska, A.C. Anderson, Structure-activity relationships of Bacillus cereus and 1048 
Bacillus anthracis dihydrofolate reductase: Toward the identification of new potent 1049 
drug leads, Antimicrob. Agents Chemother., 50 (2006) 3435–3443. 1050 
[98] E.W. Barrow, J. Dreier, S. Reinelt, P.C. Bourne, W.W. Barrow, In vitro efficacy of 1051 
new antifolates against trimethoprim-resistant Bacillus anthracis, Antimicrob. Agents 1052 
Chemother., 51 (2007) 4447–4452. 1053 
[99] J.M. Beierlein, K.M. Frey, D.B. Bolstad, P.M. Pelphrey, T.M. Joska, A.E. Smith, N.D. 1054 
Priestley, D.L. Wright, A.C. Anderson, Synthetic and crystallographic studies of a new 1055 
inhibitor series targeting Bacillus anthracis dihydrofolate reductase, J. Med. Chem., 51 1056 
(2008) 7532–7540. 1057 
[100] B.C. Bennett, H. Xu, R.F. Simmerman, R.E. Lee, C.G. Dealwis, Crystal structure of 1058 
the anthrax drug target, Bacillus anthracis dihydrofolate reductase, J. Med. Chem., 50 1059 
(2007) 4374–4381. 1060 
[101] J.M. Beierlein, L. Deshmukh, K.M. Frey, O. Vinogradova, A.C. Anderson, The 1061 
solution structure of Bacillus anthracis dihydrofolate reductase yields insight into the 1062 
analysis of structure-activity relationships for novel inhibitors, Biochemistry, 48 (2009) 1063 
4100–4108. 1064 
[102] J.M. Beierlein, N.G. Karri, A.C. Anderson, Targeted mutations of bacillus anthracis 1065 
dihydrofolate reductase condense complex structure-activity relationships, J. Med. 1066 
Chem., 53 (2010) 7327–7336. 1067 
[103] C.R. Bourne, R.A. Bunce, P.C. Bourne, K.D. Berlin, E.W. Barrow, W.W. Barrow, 1068 
Crystal structure of Bacillus anthracis dihydrofolate reductase with the 1069 
dihydrophthalazine-based trimethoprim derivative RAB1 provides a structural 1070 
explanation of potency and selectivity, Antimicrob. Agents Chemother., 53 (2009) 1071 
3065–3073. 1072 
[104] B. Nammalwar, R.A. Bunce, K.D. Berlin, C.R. Bourne, P.C. Bourne, E.W. Barrow, 1073 
W.W. Barrow, Synthesis and biological activity of substituted 2,4-diaminopyrimidines 1074 
that inhibit Bacillus anthracis, Eur. J. Med. Chem., 54 (2012) 387–396. 1075 
[105] B. Nammalwar, C.R. Bourne, R.A. Bunce, N. Wakeham, P.C. Bourne, K. Ramnarayan, 1076 
S. Mylvaganam, K.D. Berlin, E.W. Barrow, W.W. Barrow, Inhibition of Bacterial 1077 
Dihydrofolate Reductase by 6-Alkyl-2,4-diaminopyrimidines, ChemMedChem, 7 1078 
(2012) 1974–1982. 1079 
[106] C.R. Bourne, N. Wakeham, B. Nammalwar, V. Tseitin, P.C. Bourne, E.W. Barrow, S. 1080 
Mylvaganam, K. Ramnarayan, R.A. Bunce, K.D. Berlin, W.W. Barrow, Structure-1081 
activity relationship for enantiomers of potent inhibitors of B anthracis dihydrofolate 1082 
reductase, Biochim. Biophys. Acta - Proteins Proteomics, 1834 (2013) 46–52. 1083 
[107] B. Nammalwar, N. Muddala, C. Bourne, M. Henry, P. Bourne, R. Bunce, E. Barrow, 1084 
K. Berlin, W. Barrow, Synthesis and Biological Evaluation of 2,4-Diaminopyrimidine-1085 
Based Antifolate Drugs against Bacillus anthracis, Molecules, 19 (2014) 3231–3246. 1086 
[108] B. Nammalwar, C.R. Bourne, N. Wakeham, P.C. Bourne, E.W. Barrow, N.P. Muddala, 1087 
Author manuscript published in: BBA - General Subjects 
54 
R.A. Bunce, K.D. Berlin, W.W. Barrow, Modified 2,4-diaminopyrimidine-based 1088 
dihydrofolate reductase inhibitors as potential drug scaffolds against Bacillus anthracis, 1089 
Bioorg. Med. Chem., 23 (2015) 203–211. 1090 
[109] N. Muddala, B. Nammalwar, S. Selvaraju, C. Bourne, M. Henry, R. Bunce, K. Berlin, 1091 
E. Barrow, W. Barrow, Evaluation of New Dihydrophthalazine-Appended 2,4-1092 
Diaminopyrimidines against Bacillus anthracis: Improved Syntheses Using a New 1093 
Pincer Complex, Molecules, 20 (2015) 7222–7244. 1094 
[110] C.R. Bourne, N. Wakeham, N. Webb, B. Nammalwar, R.A. Bunce, K.D. Berlin, W.W. 1095 
Barrow, The structure and competitive substrate inhibition of dihydrofolate reductase 1096 
from enterococcus faecalis reveal restrictions to cofactor docking, Biochemistry, 53 1097 
(2014) 1228–1238. 1098 
[111] A. Morgan, C. Cofer, D.L. Stevens, Iclaprim: a novel dihydrofolate reductase inhibitor 1099 
for skin and soft tissue infections, Futur. Microviology, 4 (2009) 131–144. 1100 
[112] M. Kurosu, S. Siricilla, K. Mitachi, Advances in MRSA drug discovery: where are we 1101 
and where do we need to be?, Expert Opin Drug Discov, 8 (2013) 1095–1116. 1102 
[113] C.R. Bourne, E.W. Barrow, R.A. Bunce, P.C. Bourne, K.D. Berlin, W.W. Barrow, 1103 
Inhibition of antibiotic-resistant Staphylococcus aureus by the broad-spectrum 1104 
dihydrofolate reductase inhibitor RAB1, Antimicrob. Agents Chemother., 54 (2010) 1105 
3825–3833. 1106 
[114] P.M. Pelphrey, V.M. Popov, T.M. Joska, J.M. Beierlein, E.S.D. Bolstad, Y.A. 1107 
Fillingham, D.L. Wright, A.C. Anderson, Highly efficient ligands for dihydrofolate 1108 
reductase from Cryptosporidium hominis and Toxoplasma gondii inspired by structural 1109 
analysis, J. Med. Chem., 50 (2007) 940–50. 1110 
[115] J. Liu, D.B. Bolstad, A.E. Smith, N.D. Priestley, D.L. Wright, A.C. Anderson, 1111 
Structure-Guided Development of Efficacious Antifungal Agents Targeting Candida 1112 
glabrata Dihydrofolate Reductase, Chem. Biol., 15 (2008) 990–996. 1113 
[116] K.M. Frey, J. Liu, M.N. Lombardo, D.B. Bolstad, D.L. Wright, A.C. Anderson, Crystal 1114 
Structures of Wild-type and Mutant Methicillin-resistant Staphylococcus aureus 1115 
Dihydrofolate Reductase Reveal an Alternate Conformation of NADPH That May Be 1116 
Linked to Trimethoprim Resistance, J. Mol. Biol., 387 (2009) 1298–1308. 1117 
[117] K. Viswanathan, K.M. Frey, E.W. Scocchera, B.D. Martin, P.W. Swain, J.B. Alverson, 1118 
N.D. Priestley, A.C. Anderson, D.L. Wright, Toward new therapeutics for skin and soft 1119 
tissue infections: Propargyl-Linked antifolates are potent inhibitors of MRSA and 1120 
streptococcus pyogenes, PLoS One, 7 (2012) 1–9. 1121 
[118] K.M. Frey, K. Viswanathan, D.L. Wright, A.C. Anderson, Prospective screening of 1122 
novel antibacterial inhibitors of dihydrofolate reductase for mutational resistance, 1123 
Antimicrob. Agents Chemother., 56 (2012) 3556–3562. 1124 
[119] K.M. Lamb, N. G-Dayanandan, D.L. Wright, A.C. Anderson, Elucidating features that 1125 
drive the design of selective antifolates using crystal structures of human dihydrofolate 1126 
reductase, Biochemistry, 52 (2013) 7318–7326. 1127 
[120] S. Keshipeddy, S.M. Reeve, A.C. Anderson, D.L. Wright, Non-racemic Antifolates 1128 
Stereo-selectively Recruit Alternate Cofactors and Overcome Resistance in S aureus, J. 1129 
Author manuscript published in: BBA - General Subjects 
55 
Am. Chem. Soc., (2015) 150622174016006. 1130 
[121] K.M. Lamb, M.N. Lombardo, J. Alverson, N.D. Priestley, D.L. Wright, A.C. 1131 
Anderson, Crystal structures of klebsiella pneumoniae dihydrofolate reductase bound 1132 
to propargyl-linked antifolates reveal features for potency and selectivity, Antimicrob. 1133 
Agents Chemother., 58 (2014) 7484–7491. 1134 
[122] S. Khabnadideh, D. Pez, A. Musso, R. Brun, L.M. Ruiz Pérez, D. González-1135 
Pacanowska, I.H. Gilbert, Design, synthesis and evaluation of 2,4-diaminoquinazolines 1136 
as inhibitors of trypanosomal and leishmanial dihydrofolate reductase, Bioorganic 1137 
Med. Chem., 13 (2005) 2637–2649. 1138 
[123] X. Li, M. Hilgers, M. Cunningham, Z. Chen, M. Trzoss, J. Zhang, L. Kohnen, T. Lam, 1139 
C. Creighton, K. Gc, K. Nelson, B. Kwan, M. Stidham, V. Brown-Driver, K.J. Shaw, J. 1140 
Finn, Structure-based design of new DHFR-based antibacterial agents: 7-aryl-2,4-1141 
diaminoquinazolines, Bioorganic Med. Chem. Lett., 21 (2011) 5171–5176. 1142 
[124] T. Lam, M.T. Hilgers, M.L. Cunningham, B.P. Kwan, K.J. Nelson, V. Brown-Driver, 1143 
V. Ong, M. Trzoss, G. Hough, K.J. Shaw, J. Finn, Structure-based design of new 1144 
dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-1145 
diaminoquinazolines, J. Med. Chem., 57 (2014) 651–668. 1146 
[125] M. Kobayashi, T. Kinjo, Y. Koseki, C.R. Bourne, W.W. Barrow, S. Aoki, 1147 
Identification of novel potential antibiotics against Staphylococcus using structure-1148 
based drug screening targeting dihydrofolate reductase, J. Chem. Inf. Model., 54 (2014) 1149 
1242–1253. 1150 
[126] I. Chatterjee, A. Kriegeskorte, A. Fischer, S. Deiwick, N. Theimann, R.A. Proctor, G. 1151 
Peters, M. Herrmann, B.C. Kahl, In vivo mutations of thymidylate synthase (Encoded 1152 
by thyA) are responsible for thymidine dependency in clinical small-colony variants of 1153 
Staphylococcus aureus, J. Bacteriol., 190 (2008) 834–842. 1154 
[127] A. Kriegeskorte, N.I. Lorè, A. Bragonzi, C. Riva, M. Kelkenberg, K. Becker, R.A. 1155 
Proctor, G. Peters, B.C. Kahl, Thymidine-Dependent Staphylococcus aureus Small-1156 
Colony Variants Are Induced by Trimethoprim-Sulfamethoxazole (SXT) and Have 1157 
Increased Fitness during SXT Challenge, Antimicrob. Agents Chemother., 59 (2015) 1158 
7265–72. 1159 
[128] S. Besier, J. Zander, B.C. Kahl, P. Kraiczy, V. Brade, T.A. Wichelhaus, The 1160 
thymidine-dependent small-colony-variant phenotype is associated with 1161 
hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates, 1162 
Antimicrob. Agents Chemother., 52 (2008) 2183–2189. 1163 
[129] Q. Zhang, T. Nguyen, M. McMichael, S.E. Velu, J. Zou, X. Zhou, H. Wu, New small-1164 
molecule inhibitors of dihydrofolate reductase inhibit Streptococcus mutans, Int. J. 1165 
Antimicrob. Agents, 46 (2015) 174–182. 1166 
[130] S. Chakraborty, T. Gruber, C.E. Barry, H.I. Boshoff, K.Y. Rhee, Para-aminosalicylic 1167 
acid acts as an alternative substrate of folate metabolism in Mycobacterium 1168 
tuberculosis, Science, 339 (2013) 88–91. 1169 
[131] J. Zheng, E.J. Rubin, P. Bifani, V. Mathys, V. Lim, M. Au, J. Jang, J. Nam, T. Dick, 1170 
J.R. Walker, K. Pethe, L.R. Camacho, Para-aminosalicylic acid is a prodrug targeting 1171 
Author manuscript published in: BBA - General Subjects 
56 
dihydrofolate reductase in mycobacterium tuberculosis, J. Biol. Chem., 288 (2013) 1172 
23447–23456. 1173 
[132] M.R. Nixon, K.W. Saionz, M.S. Koo, M.J. Szymonifka, H. Jung, J.P. Roberts, M. 1174 
Nandakumar, A. Kumar, R. Liao, T. Rustad, J.C. Sacchettini, K.Y. Rhee, J.S. 1175 
Freundlich, D.R. Sherman, Folate pathway disruption leads to critical disruption of 1176 
methionine derivatives in mycobacterium tuberculosis, Chem. Biol., 21 (2014) 819–1177 
830. 1178 
[133] V. Mathys, R. Wintjens, P. Lefevre, J. Bertout, A. Singhal, M. Kiass, N. Kurepina, 1179 
X.M. Wang, B. Mathema, A. Baulard, B.N. Kreiswirth, P. Bifani, Molecular genetics 1180 
of para-aminosalicylic acid resistance in clinical isolates and spontaneous mutants of 1181 
Mycobacterium tuberculosis, Antimicrob. Agents Chemother., 53 (2009) 2100–2109. 1182 
[134] F. Zhao, X. De Wang, L.N. Erber, M. Luo, A.Z. Guo, S.S. Yang, J. Gu, B.J. Turman, 1183 
Y.R. Gao, D.F. Li, Z.Q. Cui, Z.P. Zhang, L.J. Bi, A.D. Baughn, X.E. Zhang, J.Y. 1184 
Deng, Binding pocket alterations in dihydrofolate synthase confer resistance to para-1185 
aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis, Antimicrob. 1186 
Agents Chemother., 58 (2014) 1479–1487. 1187 
[135] Y. Minato, J.M. Thiede, S.L. Kordus, E.J. McKlveen, B.J. Turman, A.D. Baughn, 1188 
Mycobacterium tuberculosis folate metabolism and the mechanistic basis for para-1189 
aminosalicylic acid susceptibility and resistance, Antimicrob. Agents Chemother., 59 1190 
(2015) 5097–5106. 1191 
[136] Y.-S. Cheng, J.C. Sacchettini, Structural Insights into Mycobacterium tuberculosis 1192 
Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to 1193 
para -Aminosalicylic Acid Resistance, Biochemistry, (2016) acs.biochem.5b00993. 1194 
[137] K.A. Wolff, L. Nguyen, Strategies for potentiation of ethionamide and folate 1195 
antagonists against Mycobacterium tuberculosis, Expert Rev. Anti. Infect. Ther., 10 1196 
(2012) 971–81. 1197 
[138] L.B. Gerum, J.E. Ulmer, D.P. Jacobus, N.P. Jensen, D.R. Sherman, C.H. Sibley, Novel 1198 
Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit 1199 
Mycobacterium tuberculosis dihydrofolate reductase Novel Saccharomyces cerevisiae 1200 
screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis 1201 
dihydrofolate red, Society, 46 (2002) 3362–3369. 1202 
[139] A. Kumar, M. Zhang, L. Zhu, R.P. Liao, C. Mutai, S. Hafsat, D.R. Sherman, M.-W. 1203 
Wang, High-throughput Screening and Sensitized Bacteria Identify an M tuberculosis 1204 
Dihydrofolate Reductase Inhibitor with Whole Cell Activity, PLoS One, 7 (2012) 1205 
e39961. 1206 
[140] R. Li, R. Sirawaraporn, P. Chitnumsub, W. Sirawaraporn, J. Wooden, F. Athappilly, S. 1207 
Turley, W.G. Hol, Three-dimensional structure of M tuberculosis dihydrofolate 1208 
reductase reveals opportunities for the design of novel tuberculosis drugs, J. Mol. Biol., 1209 
295 (2000) 307–323. 1210 
[141] M.H.R.I. El-Hamamsy, A.W. Smith, A.S. Thompson, M.D. Threadgill, Structure-based 1211 
design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate 1212 
reductase from Mycobacterium tuberculosis, Bioorg. Med. Chem., 15 (2007) 4552–76. 1213 
Author manuscript published in: BBA - General Subjects 
57 
[142] W. Hong, Y. Wang, Z. Chang, Y. Yang, J. Pu, T. Sun, S. Kaur, J.C. Sacchettini, H. 1214 
Jung, W. Lin Wong, L. Fah Yap, Y. Fong Ngeow, I.C. Paterson, H. Wang, The 1215 
identification of novel Mycobacterium tuberculosis DHFR inhibitors and the 1216 
investigation of their binding preferences by using molecular modelling, Sci. Rep., 5 1217 
(2015) 15328. 1218 
[143] A. Kumar, A. Guardia, G. Colmenarejo, E. Pérez, R.R. Gonzalez, P. Torres, D. Calvo, 1219 
R.M. Gómez, F. Ortega, E. Jiménez, R.C. Gabarro, J. Rullás, L. Ballell, D.R. Sherman, 1220 
A Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis, 1221 
ACS Infect. Dis., (2015) acsinfecdis.5b00063. 1222 
[144] A.C. Lele, A. Raju, M.K. Ray, M.G.R. Rajan, M.S. Degani, Design and Synthesis of 1223 
Diaminotriazines as Anti-Tuberculosis DHFR Inhibitors, Curr. Res. Drug Discov., 1 1224 
(2014) 45–50. 1225 
[145] N.R. Tawari, S. Bag, A. Raju, A.C. Lele, R. Bairwa, M.K. Ray, M. Rajan, L.U. 1226 
Nawale, D. Sarkar, M.S. Degani, Rational drug design, synthesis and biological 1227 
evaluation of dihydrofolate reductase inhibitors as antituberculosis agents, Future Med. 1228 
Chem., 7 (2015) 979–988. 1229 
[146] A.C. Lele, A. Raju, M.P. Khambete, M.K. Ray, M.G.R. Rajan, M.A. Arkile, N.J. 1230 
Jadhav, D. Sarkar, M.S. Degani, Design and Synthesis of a Focused Library of 1231 
Diamino Triazines as Potential Mycobacterium tuberculosis DHFR Inhibitors, ACS 1232 
Med. Chem. Lett., 6 (2015) 1140–1144. 1233 
[147] G. Mugumbate, K.A. Abrahams, J.A.G. Cox, G. Papadatos, G. van Westen, J. Lelièvre, 1234 
S.T. Calus, N.J. Loman, L. Ballell, D. Barros, J.P. Overington, G.S. Besra, 1235 
Mycobacterial dihydrofolate reductase inhibitors identified using chemogenomic 1236 
methods and in vitro validation, PLoS One, 10 (2015) e0121492. 1237 
[148] L.F. Kuyper, D.P. Baccanari, M.L. Jones, R.N. Hunter, R.L. Tansik, S.S. Joyner, C.M. 1238 
Boytos, S.K. Rudolph, V. Knick, H.R. Wilson, J.M. Caddell, H.S. Friedman, J.C.W. 1239 
Comley, J.N. Stables, High-affinity inhibitors of dihydrofolate reductase: 1240 
Antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-1241 
f]quinazolines with small molecular size, J. Med. Chem., 39 (1996) 892–903. 1242 
[149] T. Otzen, E.G. Wempe, B. Kunz, R. Bartels, G. Lehwark-Yvetot, W. Hänsel, K.J. 1243 
Schaper, J.K. Seydel, Folate-Synthesizing Enzyme System as Target for Development 1244 
of Inhibitors and Inhibitor Combinations against Candida albicans - Synthesis and 1245 
Biological Activity of New 2,4-Diaminopyrimidines and 4′-Substituted 4-1246 
Aminodiphenyl Sulfones, J. Med. Chem., 47 (2004) 240–253. 1247 
[150] J.L. Paulsen, J. Liu, D.B. Bolstad, A.E. Smith, N.D. Priestley, D.L. Wright, A.C. 1248 
Anderson, In vitro biological activity and structural analysis of 2,4-diamino-5-(2’-1249 
arylpropargyl)pyrimidine inhibitors of Candida albicans, Bioorganic Med. Chem., 17 1250 
(2009) 4866–4872. 1251 
[151] J. Liu, D.B. Bolstad, A.E. Smith, N.D. Priestley, D.L. Wright, A.C. Anderson, Probing 1252 
the active site of Candida glabrata dihydrofolate reductase with high resolution crystal 1253 
structures and the synthesis of new inhibitors, Chem. Biol. Drug Des., 73 (2009) 62–1254 
74. 1255 
[152] J.L. Paulsen, S.D. Bendel, A.C. Anderson, Crystal Structures of Candida albicans 1256 
Author manuscript published in: BBA - General Subjects 
58 
Dihydrofolate Reductase Bound to Propargyl-Linked Antifolates Reveal the Flexibility 1257 
of Active Site Loop Residues Critical for Ligand Potency and Selectivity, Chem. Biol. 1258 
Drug Des., 78 (2011) 505–512. 1259 
[153] J.L. Paulsen, K. Viswanathan, D.L. Wright, A.C. Anderson, Structural analysis of the 1260 
active sites of dihydrofolate reductase from two species of Candida uncovers ligand-1261 
induced conformational changes shared among species, Bioorganic Med. Chem. Lett., 1262 
23 (2013) 1279–1284. 1263 
[154] N. G-Dayanandan, J.L. Paulsen, K. Viswanathan, S. Keshipeddy, M.N. Lombardo, W. 1264 
Zhou, K.M. Lamb, A.E. Sochia, J.B. Alverson, N.D. Priestley, D.L. Wright, A.C. 1265 
Anderson, Propargyl-linked antifolates are dual inhibitors of Candida albicans and 1266 
Candida glabrata, J. Med. Chem., 57 (2014) 2643–2656. 1267 
[155] Y.T. Kumar, Sivakumar Prasanth Jasrai, H.A. Pandya, Applications of Receptor- and 1268 
Ligand-based Models in Inverse Docking Experiments: Recognition of Dihydrofolate 1269 
Reductase using 7, 8-dialkyl-1,3-diaminopyrrolo[3, 2-f]quinazolines, Curr. Comput. 1270 
Aided-Drug Des., 12 (2015) 1–14. 1271 
[156] K.M. Ivanetich, D. V. Santi, Bifunctional thymidylate synthase-dihydrofolate reductase 1272 
in protozoa, Exp. Parasitol., 70 (1990) 367–371. 1273 
[157] C.K.T. Pang, S.K. De, J. White, F.S. Buckner, G. Varani, P.K. Rathod, Differential 1274 
drug binding by the highly conserved Plasmodium falciparum thymidylate synthase, 1275 
Mol. Biochem. Parasitol., 143 (2005) 121–124. 1276 
[158] D.R. Knighton, C.-C. Kan, E. Howland, C.A. Janson, Z. Hostomska, K.M. Welsh, D.A. 1277 
Matthews, Structure of and kinetic channelling in bifunctional dihydrofolate reductase–1278 
thymidylate synthase, Nat. Struct. Mol. Biol., 1 (1994) 186 – 194. 1279 
[159] W. Edward Martucci, M. Udier-Blagovic, C. Atreya, O. Babatunde, M.A. Vargo, W.L. 1280 
Jorgensen, K.S. Anderson, Novel non-active site inhibitor of Cryptosporidium hominis 1281 
TS-DHFR identified by a virtual screen, Bioorganic Med. Chem. Lett., 19 (2009) 418–1282 
423. 1283 
[160] W.E. Martucci, J.M. Rodriguez, M.A. Vargo, M. Marr, A.D. Hamilton, K.S. Anderson, 1284 
Exploring novel strategies for AIDS protozoal pathogens: α-helix mimetics targeting a 1285 
key allosteric protein-protein interaction in C hominis TS-DHFR, Med. Chem. 1286 
Commun., 4 (2013) 1247–1256. 1287 
[161] H. Sharma, M.J. Landau, T.J. Sullivan, V.P. Kumar, M.K. Dahlgren, W.L. Jorgensen, 1288 
K.S. Anderson, Virtual screening reveals allosteric inhibitors of the Toxoplasma gondii 1289 
thymidylate synthase-dihydrofolate reductase, Bioorg. Med. Chem. Lett., 24 (2014) 1290 
1232–5. 1291 
[162] M.J. Landau, H. Sharma, K.S. Anderson, Selective peptide inhibitors of bifunctional 1292 
thymidylate synthase-dihydrofolate reductase from Toxoplasma gondii provide insights 1293 
into domain-domain communication and allosteric regulation, Protein Sci., 22 (2013) 1294 
1161–73. 1295 
[163] Y. Yuthavong, B. Tarnchompoo, T. Vilaivan, P. Chitnumsub, S. Kamchonwongpaisan, 1296 
S.A. Charman, D.N. McLennan, K.L. White, L. Vivas, E. Bongard, C. 1297 
Thongphanchang, S. Taweechai, J. Vanichtanankul, R. Rattanajak, U. Arwon, P. 1298 
Author manuscript published in: BBA - General Subjects 
59 
Fantauzzi, J. Yuvaniyama, W.N. Charman, D. Matthews, Malarial dihydrofolate 1299 
reductase as a paradigm for drug development against a resistance-compromised target, 1300 
Proc. Natl. Acad. Sci., 109 (2012) 16823–16828. 1301 
[164] J. Yuvaniyama, P. Chitnumsub, S. Kamchonwongpaisan, J. Vanichtanankul, W. 1302 
Sirawaraporn, P. Taylor, M.D. Walkinshaw, Y. Yuthavong, Insights into antifolate 1303 
resistance from malarial DHFR-TS structures, Nat. Struct. Biol., 10 (2003) 357–365. 1304 
[165] N. Drinkwater, S. McGowan, From crystal to compound: structure-based antimalarial 1305 
drug discovery, Biochem. J., 461 (2014) 349–69. 1306 
[166] S. Abbat, V. Jain, P. V Bharatam, Origins of the specificity of inhibitor P218 toward 1307 
wild-type and mutant PfDHFR:  a molecular dynamics analysis, J. Biomol. Struct. 1308 
Dyn., (2014) 1–16. 1309 
[167] R. Giridhar, R.S. Tamboli, D.G. Prajapati, S. Soni, S. Gupta, M.R. Yadav, Synthesis of 1310 
novel 4,6-diaryl-2-aminopyrimidines as potential antiplasmodial agents, Med. Chem. 1311 
Res., 22 (2013) 3309–3315. 1312 
[168] B. Borkakoty, K. Sarma, P. Parida, A. Prakash, P. Kishore Mohapatra, J. Mahanta, In 1313 
Silico Screening of Antifolate Based Novel Inhibitors from Brucea mollis Wall ex kurz 1314 
Against Quadruple Mutant Drug Resistant PfDHFR, Comb. Chem. High Throughput 1315 
Screen., 17 (2014) 681–693. 1316 
[169] W. Mokmak, S. Chunsrivirot, S. Hannongbua, Y. Yuthavong, S. Tongsima, S. 1317 
Kamchonwongpaisan, Molecular dynamics of interactions between rigid and flexible 1318 
antifolates and dihydrofolate reductase from pyrimethamine-sensitive and 1319 
pyrimethamine-resistant Plasmodium falciparum, Chem. Biol. Drug Des., 84 (2014) 1320 
450–461. 1321 
[170] L. Adane, S. Bhagat, M. Arfeen, S. Bhatia, R. Sirawaraporn, W. Sirawaraporn, A.K. 1322 
Chakraborti, P. V. Bharatam, Design and synthesis of guanylthiourea derivatives as 1323 
potential inhibitors of Plasmodium falciparum dihydrofolate reductase enzyme, 1324 
Bioorganic Med. Chem. Lett., 24 (2014) 613–617. 1325 
[171] A. Heinberg, E. Siu, C. Stern, E.A. Lawrence, M.T. Ferdig, K.W. Deitsch, L.A. 1326 
Kirkman, Direct evidence for the adaptive role of copy number variation on antifolate 1327 
susceptibility in Plasmodium falciparum, Mol. Microbiol., 88 (2013) 702–712. 1328 
[172] D.J. Bzik, W.B. Li, T. Horii, J. Inselburg, Molecular cloning and sequence analysis of 1329 
the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene, Proc. 1330 
Natl. Acad. Sci. U. S. A., 84 (1987) 8360–4. 1331 
[173] W. Sirawaraporn, R. Sertsrivanich, R.G. Booth, C. Hansch, R.A. Neal, D. V. Santi, 1332 
Selective inhibition of Leishmania dihydrofolate reductase and Leishmania growth by 1333 
5-benzyl-2,4-diaminopyrimidines, Mol. Biochem. Parasitol., 31 (1988) 79–85. 1334 
[174] S.F. Chowdhury, V.B. Villamor, R.H. Guerrero, I. Leal, R. Brun, S.L. Croft, J.M. 1335 
Goodman, L. Maes, L.M. Ruiz-Perez, D.G. Pacanowska, I.H. Gilbert, Design, 1336 
synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate 1337 
reductase, J. Med. Chem., 42 (1999) 4300–4312. 1338 
[175] L. Maganti, P. Manoharan, N. Ghoshal, Probing the structure of Leishmania donovani 1339 
chagasi DHFR-TS: Comparative protein modeling and protein-ligand interaction 1340 
Author manuscript published in: BBA - General Subjects 
60 
studies, J. Mol. Model., 16 (2010) 1539–1547. 1341 
[176] R. Rajasekaran, Y.P.P. Chen, Probing the structure of Leishmania major DHFR TS and 1342 
structure based virtual screening of peptide library for the identification of anti-1343 
Leishmanial leads, J. Mol. Model., 18 (2012) 4089–4100. 1344 
[177] P. Palit, A. Hazra, A. Maity, R.S.K. Vijayan, P. Manoharan, S. Banerjee, N.B. Mondal, 1345 
N. Ghoshal, N. Ali, Discovery of safe and orally effective 4-aminoquinaldine 1346 
analogues as apoptotic inducers with activity against experimental visceral 1347 
leishmaniasis, Antimicrob. Agents Chemother., 56 (2012) 432–445. 1348 
[178] S.F. Chowdhury, R.H. Guerrero, R. Brun, L.M. Ruiz-Perez, D.G. Pacanowska, I.H. 1349 
Gilbert, Synthesis and testing of 5-benzyl-2,4-diaminopyrimidines as potential 1350 
inhibitors of leishmanial and trypanosomal dihydrofolate reductase, J Enzym. Inhib 1351 
Med Chem, 17 (2002) 293–302. 1352 
[179] D. Pez, I. Leal, F. Zuccotto, C. Boussard, R. Brun, S.L. Croft, V. Yardley, L.M. Ruiz 1353 
Perez, D. Gonzalez Pacanowska, I.H. Gilbert, 2,4-Diaminopyrimidines as inhibitors of 1354 
leishmanial and trypanosomal dihydrofolate reductase, Bioorganic Med. Chem., 11 1355 
(2003) 4693–4711. 1356 
[180] O. Senkovich, V. Bhatia, N. Garg, O. Senkovich, V. Bhatia, N. Garg, Lipophilic 1357 
Antifolate Trimetrexate Is a Potent Inhibitor of Trypanosoma cruzi : Prospect for 1358 
Chemotherapy of Chagas ’ Disease Lipophilic Antifolate Trimetrexate Is a Potent 1359 
Inhibitor of Trypanosoma cruzi : Prospect for Chemotherapy of Chagas ’ Disease, 49 1360 
(2005) 3234–3238. 1361 
[181] N. Schormann, O. Senkovich, K. Walker, D.L. Wright, A.C. Anderson, A. Rosowsky, 1362 
S. Ananthan, B. Shinkre, S. Velu, D. Chattopadhyay, Structure-based approach to 1363 
pharmacophore identification, in silico screening, and three-dimensional quantitative 1364 
structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate 1365 
reductase function, Proteins, 73 (2008) 889–901. 1366 
[182] O. Senkovich, N. Schormann, D. Chattopadhyay, Structures of dihydrofolate reductase-1367 
thymidylate synthase of trypanosoma cruzi in the folate-free state and in complex with 1368 
two antifolate drugs, trimetrexate and methotrexate, Acta Crystallogr. Sect. D Biol. 1369 
Crystallogr., 65 (2009) 704–716. 1370 
[183] P. Chitnumsub, J. Yuvaniyama, T. Chahomchuen, T. Vilaivan, Y. Yuthavong, 1371 
Crystallization and preliminary crystallographic studies of dihydrofolate reductase-1372 
thymidylate synthase from Trypanosoma cruzi, the Chagas disease pathogen, Acta 1373 
Crystallogr. Sect. F. Struct. Biol. Cryst. Commun., 65 (2009) 1175–8. 1374 
[184] N. Schormann, S.E. Velu, S. Murugesan, O. Senkovich, K. Walker, B.C. Chenna, B. 1375 
Shinkre, A. Desai, D. Chattopadhyay, Synthesis and characterization of potent 1376 
inhibitors of Trypanosoma cruzi dihydrofolate reductase, Bioorg. Med. Chem., 18 1377 
(2010) 4056–4066. 1378 
[185] J. Vanichtanankul, S. Taweechai, J. Yuvaniyama, T. Vilaivan, P. Chitnumsub, S. 1379 
Kamchonwongpaisan, Y. Yuthavong, Trypanosomal dihydrofolate reductase reveals 1380 
natural antifolate resistance, ACS Chem. Biol., 6 (2011) 905–911. 1381 
[186] B.A. Fox, D.J. Bzik, De novo pyrimidine biosynthesis is required for virulence of 1382 
Author manuscript published in: BBA - General Subjects 
61 
Toxoplasma gondii, Nature, 415 (2002) 926–9. 1383 
[187] M.H. Iltzsch, Pyrimidine salvage pathways in Toxoplasma gondii, J. Eukaryot. 1384 
Microbiol., 40 (1993) 24–8. 1385 
[188] A. Gangjee, W. Li, J. Yang, R.L. Kisliuk, Design, synthesis, and biological evaluation 1386 
of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-1387 
d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors, J. 1388 
Med. Chem., 51 (2008) 68–76. 1389 
[189] D. Pacheco Homem, R. Flores, P. Tosqui, T. de Castro Rozada, E. Abicht Basso, A. 1390 
Gasparotto, F. Augusto Vicente Seixas, Homology modeling of dihydrofolate reductase 1391 
from T gondii bonded to antagonists: molecular docking and molecular dynamics 1392 
simulations, Mol. Biosyst., 9 (2013) 1308–15. 1393 
[190] N. Zaware, H. Sharma, J. Yang, R.K.V. Devambatla, S.F. Queener, K.S. Anderson, A. 1394 
Gangjee, Discovery of potent and selective inhibitors of toxoplasma gondii thymidylate 1395 
synthase for opportunistic infections, ACS Med. Chem. Lett., 4 (2013) 1148–1151. 1396 
[191] H. Sharma, M.J. Landau, M.A. Vargo, K.A. Spasov, K.S. Anderson, First three-1397 
dimensional structure of toxoplasma gondii thymidylate synthase-dihydrofolate 1398 
reductase: Insights for catalysis, interdomain interactions, and substrate channeling, 1399 
Biochemistry, 52 (2013) 7305–7317. 1400 
[192] R.H. O’Neil, R.H. Lilien, B.R. Donald, R.M. Stroud, A.C. Anderson, Phylogenetic 1401 
Classification of Protozoa Based on the Structure of the Linker Domain in the 1402 
Bifunctional Enzyme, Dihydrofolate Reductase-Thymidylate Synthase, J. Biol. Chem., 1403 
278 (2003) 52980–52987. 1404 
[193] A.C. Anderson, Two crystal structures of dihydrofolate reductase-thymidylate synthase 1405 
from Cryptosporidium hominis reveal protein-ligand interactions including a structural 1406 
basis for observed antifolate resistance, Acta Crystallogr. Sect. F. Struct. Biol. Cryst. 1407 
Commun., 61 (2005) 258–62. 1408 
[194] D.B. Bolstad, E.S.D. Bolstad, K.M. Frey, D.L. Wright, A.C. Anderson, Structure-1409 
Based Approach to the Development of Potent and Selective Inhibitors of 1410 
Dihydrofolate Reductase from Cryptosporidium, J. Med. Chem., (2008) 6839–6852. 1411 
[195] V.P. Kumar, K.M. Frey, Y. Wang, H.K. Jain, A. Gangjee, K.S. Anderson, Substituted 1412 
pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase 1413 
inhibitors, Bioorganic Med. Chem. Lett., 23 (2013) 5426–5428. 1414 
[196] A. Mukerjee, P. Iyidogan, A. Castellanos-Gonzalez, J.A. Cisneros, D. Czyzyk, A.P. 1415 
Ranjan, W.L. Jorgensen, A.C. White, J.K. Vishwanatha, K.S. Anderson, A nanotherapy 1416 
strategy significantly enhances anticryptosporidial activity of an inhibitor of 1417 
bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium, 1418 
Bioorg. Med. Chem. Lett., 25 (2015) 2065–7. 1419 
[197] W. Sirawaraporn, T. Sathitkul, R. Sirawaraporn, Y. Yuthavong, D. V Santi, Antifolate-1420 
resistant mutants of Plasmodium falciparum dihydrofolate reductase, Proc. Natl. Acad. 1421 
Sci. U. S. A., 94 (1997) 1124–1129. 1422 
[198] S. Kamchonwongpaisan, R. Quarrell, N. Charoensetakul, R. Ponsinet, T. Vilaivan, J. 1423 
Vanichtanankul, B. Tarnchompoo, W. Sirawaraporn, G. Lowe, Y. Yuthavong, 1424 
Author manuscript published in: BBA - General Subjects 
62 
Inhibitors of Multiple Mutants of Plasmodium falciparum Dihydrofolate Reductase and 1425 
Their Antimalarial Activities, J. Med. Chem., 47 (2004) 673–680. 1426 
[199] T. Dasgupta, P. Chitnumsub, C. Maneeruttanarungroj, S. Kamchonwongpaisan, S.E. 1427 
Nichols, T.M. Lyons, J. Tirado-Rives, W.L. Jorgensen, Y. Yuthavong, K.S. Anderson, 1428 
Exploiting Structural Analysis, in Silico Screening, and Serendipity To Identify Novel 1429 
Inhibitors of Drug-Resistant Falciparum Malaria, ACS Chem. Biol., 4 (2009) 29–40. 1430 
[200] A. Nzila, M. Rottmann, P. Chitnumsub, S.M. Kiara, S. Kamchonwongpaisan, C. 1431 
Maneeruttanarungroj, S. Taweechai, B.K.S. Yeung, A. Goh, S.B. Lakshminarayana, B. 1432 
Zou, J. Wong, N.L. Ma, M. Weaver, T.H. Keller, V. Dartois, S. Wittlin, R. Brun, Y. 1433 
Yuthavong, T.T. Diagana, Preclinical evaluation of the antifolate QN254, 5-chloro-1434 
n′6′- (2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug 1435 
candidate, Antimicrob. Agents Chemother., 54 (2010) 2603–2610. 1436 
[201] S. Tirakarn, P. Riangrungroj, P. Kongsaeree, M. Imwong, Y. Yuthavong, U. 1437 
Leartsakulpanich, Cloning and heterologous expression of Plasmodium ovale 1438 
dihydrofolate reductase-thymidylate synthase gene, Parasitol. Int., 61 (2012) 324–332. 1439 
[202] V. Somsak, C. Uthaipibull, P. Prommana, S. Srichairatanakool, Y. Yuthavong, S. 1440 
Kamchonwongpaisan, Transgenic Plasmodium parasites stably expressing Plasmodium 1441 
vivax dihydrofolate reductase-thymidylate synthase as in vitro and in vivo models for 1442 
antifolate screening, Malar. J., 10:291 (2011) 1–10. 1443 
[203] S. Bunyarataphan, U. Leartsakulpanich, S. Taweechai, B. Tarnchompoo, S. 1444 
Kamchonwongpaisan, Y. Yuthavong, Evaluation of the activities of pyrimethamine 1445 
analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate 1446 
reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial 1447 
complementation assays, Antimicrob. Agents Chemother., 50 (2006) 3631–7. 1448 
[204] M.A. Vargo, W.E. Martucci, K.S. Anderson, Disruption of the crossover helix impairs 1449 
dihydrofolate reductase activity in the bifunctional enzyme TS-DHFR from 1450 
Cryptosporidium hominis, Biochem. J., 417 (2009) 757–64. 1451 
[205] C.K.T. Pang, J.H. Hunter, R. Gujjar, R. Podutoori, J. Bowman, D.G. Mudeppa, P.K. 1452 
Rathod, Catalytic and ligand-binding characteristics of Plasmodium falciparum serine 1453 
hydroxymethyltransferase, Mol. Biochem. Parasitol., 168 (2009) 74–83. 1454 
[206] K. Sopitthummakhun, S. Maenpuen, Y. Yuthavong, U. Leartsakulpanich, P. Chaiyen, 1455 
Serine hydroxymethyltransferase from Plasmodium vivax is different in substrate 1456 
specificity from its homologues, FEBS J., 276 (2009) 4023–4036. 1457 
[207] S. Maenpuen, K. Sopitthummakhun, Y. Yuthavong, P. Chaiyen, U. Leartsakulpanich, 1458 
Characterization of Plasmodium falciparum serine hydroxymethyltransferase-A 1459 
potential antimalarial target, Mol. Biochem. Parasitol., 168 (2009) 63–73. 1460 
[208] W. Pornthanakasem, D. Kongkasuriyachai, C. Uthaipibull, Y. Yuthavong, U. 1461 
Leartsakulpanich, Plasmodium serine hydroxymethyltransferase: indispensability and 1462 
display of distinct localization, Malar. J., 11:387 (2012) 1–9. 1463 
[209] C. Pinthong, S. Maenpuen, W. Amornwatcharapong, Y. Yuthavong, U. 1464 
Leartsakulpanich, P. Chaiyen, Distinct biochemical properties of human serine 1465 
hydroxymethyltransferase compared with the Plasmodium enzyme: implications for 1466 
Author manuscript published in: BBA - General Subjects 
63 
selective inhibition, FEBS J., 281 (2014) 2570–2583. 1467 
[210] K. Sopitthummakhun, C. Thongpanchang, T. Vilaivan, Y. Yuthavong, P. Chaiyen, U. 1468 
Leartsakulpanich, Plasmodium serine hydroxymethyltransferase as a potential anti-1469 
malarial target: inhibition studies using improved methods for enzyme production and 1470 
assay, Malar. J., 11:194 (2012) 1–12. 1471 
[211] M.C. Witschel, M. Rottmann, A. Schwab, U. Leartsakulpanich, P. Chitnumsub, M. 1472 
Seet, S. Tonazzi, F. Stelzer, T. Mietzner, C. Mcnamara, F. Thater, A. Jaruwat, C. 1473 
Pinthong, P. Riangrungroj, M. Ou, M. Hamburger, P. Ma, L.M. Sanz-alonso, S. 1474 
Charman, S. Wittlin, et al., Inhibitors of Plasmodial Serine Hydroxymethyltransferase 1475 
(SHMT): Cocrystal Structures of Pyrazolopyrans with Potent Blood- and Liver- Stage 1476 
Activities, 58 (2015) 3117–3130. 1477 
[212] S. Chaturvedi, V. Bhakuni, Unusual structural, functional, and stability properties of 1478 
serine hydroxymethyltransferase from Mycobacterium tuberculosis, J. Biol. Chem., 1479 
278 (2003) 40793–805. 1480 
[213] S. Sharma, V. Bhakuni, Cloning and structural analysis of Mycobacterium leprae serine 1481 
hydroxymethyltransferase, Protein Expr. Purif., 55 (2007) 189–97. 1482 
[214] R. Vatsyayan, U. Roy, Molecular cloning and biochemical characterization of 1483 
Leishmania donovani serine hydroxymethyltransferase, Protein Expr. Purif., 52 (2007) 1484 
433–440. 1485 
[215] S. Gandhi, N. Gaur, S. Krishna, M.I. Siddiqi, J.K. Saxena, Arg-265: A critical residue 1486 
of L.donovani cytosolic SHMT in maintaining the binding of THF and catalysis, Exp. 1487 
Parasitol., 149 (2015) 16–23. 1488 
[216] D.G.S. Capelluto, U. Hellman, J.J. Cazzulo, J.J.B. Cannata, Purification and partial 1489 
characterization of three isoforms of serine hydroxymethyltransferase from Crithidia 1490 
fasciculata, Mol. Biochem. Parasitol., 98 (1999) 187–201. 1491 
[217] D.G. Capelluto, U. Hellman, J.J. Cazzulo, J.J. Cannata, Purification and some 1492 
properties of serine hydroxymethyltransferase from Trypanosoma cruzi, Eur. J. 1493 
Biochem., 267 (2000) 712–719. 1494 
[218] V.N. Dobrovolsky, T. Bucci, R.H. Heflich, J. Desjardins, F.C. Richardson, Mice 1495 
deficient for cytosolic thymidine kinase gene develop fatal kidney disease, Mol. Genet. 1496 
Metab., 78 (2003) 1–10. 1497 
[219] M. Thiel, S. Harder, M. Wiese, M. Kroemer, I. Bruchhaus, Involvement of a 1498 
Leishmania thymidine kinase in flagellum formation, promastigote shape and growth 1499 
as well as virulence, Mol. Biochem. Parasitol., 158 (2008) 152–62. 1500 
[220] J. Timm, C. Bosch-Navarrete, E. Recio, J.E. Nettleship, H. Rada, D. González-1501 
Pacanowska, K.S. Wilson, Structural and Kinetic Characterization of Thymidine 1502 
Kinase from Leishmania major, PLoS Negl. Trop. Dis., 9 (2015) e0003781. 1503 
[221] F. Ranjbarian, M. Vodnala, S.M. Vodnala, R. Rofougaran, L. Thelander, A. Hofer, 1504 
Trypanosoma brucei thymidine kinase is tandem protein consisting of two homologous 1505 
parts, which together enable efficient substrate binding, J. Biol. Chem., 287 (2012) 1506 
17628–36. 1507 
Author manuscript published in: BBA - General Subjects 
64 
[222] X.E. Sun, L. Sharling, M. Muthalagi, D.G. Mudeppa, K.W. Pankiewicz, K. Felczak, 1508 
P.K. Rathod, J. Mead, B. Striepen, L. Hedstrom, Prodrug activation by 1509 
Cryptosporidium thymidine kinase, J. Biol. Chem., 285 (2010) 15916–15922. 1510 
[223] Q. Cui, W.S. Shin, Y. Luo, J. Tian, H. Cui, D. Yin, Thymidylate Kinase: An Old Topic 1511 
Brings New Perspectives, Curr. Med. Chem., 20 (2013) 1286 – 1305. 1512 
[224] G. Martínez-Botella, J.N. Breen, J.E.S. Duffy, J. Dumas, B. Geng, I.K. Gowers, O.M. 1513 
Green, S. Guler, M.F. Hentemann, F.A. Hernandez-Juan, D. Joseph-McCarthy, S. 1514 
Kawatkar, N.A. Larsen, O. Lazari, J.T. Loch, J.A. Macritchie, A.R. McKenzie, J. V. 1515 
Newman, N.B. Olivier, L.G. Otterson, et al., Discovery of selective and potent 1516 
inhibitors of gram-positive bacterial thymidylate kinase (TMK), J. Med. Chem., 55 1517 
(2012) 10010–10021. 1518 
[225] T.A. Keating, J. V. Newman, N.B. Olivier, L.G. Otterson, B. Andrews, P.A. Boriack-1519 
Sjodin, J.N. Breen, P. Doig, J. Dumas, E. Gangl, O.M. Green, S.Y. Guler, M.F. 1520 
Hentemann, D. Joseph-Mccarthy, S. Kawatkar, A. Kutschke, J.T. Loch, A.R. 1521 
McKenzie, S. Pradeepan, S. Prasad, et al., In vivo validation of thymidylate kinase 1522 
(TMK) with a rationally designed, selective antibacterial compound, ACS Chem. Biol., 1523 
7 (2012) 1866–1872. 1524 
[226] J.Y. Choi, M.S. Plummer, J. Starr, C.R. Desbonnet, H. Soutter, J. Chang, J.R. Miller, 1525 
K. Dillman, A.A. Miller, W.R. Roush, Structure guided development of novel 1526 
thymidine mimetics targeting Pseudomonas aeruginosa thymidylate kinase: From hit to 1527 
lead generation, J. Med. Chem., 55 (2012) 852–870. 1528 
[227] V. Vanheusden, H. Munier-Lehmann, M. Froeyen, L. Dugué, A. Heyerick, D. De 1529 
Keukeleire, S. Pochet, R. Busson, P. Herdewijn, S. Van Calenbergh, 3-C-branched-1530 
chain-substituted nucleosides and nucleotides as potent inhibitors of Mycobacterium 1531 
tuberculosis thymidine monophosphate kinase, J. Med. Chem., 46 (2003) 3811–3821. 1532 
[228] K.S. Toti, F. Verbeke, M.D.P. Risseeuw, V. Frecer, H. Munier-Lehmann, S. Van 1533 
Calenbergh, Synthesis and evaluation of 5′-modified thymidines and 5-hydroxymethyl-1534 
2′-deoxyuridines as Mycobacterium tuberculosis thymidylate kinase inhibitors, 1535 
Bioorganic Med. Chem., 21 (2013) 257–268. 1536 
[229] C. Gasse, D. Douguet, V. Huteau, G. Marchal, H. Munier-Lehmann, S. Pochet, 1537 
Substituted benzyl-pyrimidines targeting thymidine monophosphate kinase of 1538 
Mycobacterium tuberculosis: Synthesis and in vitro anti-mycobacterial activity, 1539 
Bioorganic Med. Chem., 16 (2008) 6075–6085. 1540 
[230] O. Familiar, H. Munier-Lehmann, J.A. Aínsa, M.J. Camarasa, M.J. Pérez-Pérez, 1541 
Design, synthesis and inhibitory activity against Mycobacterium tuberculosis 1542 
thymidine monophosphate kinase of acyclic nucleoside analogues with a distal 1543 
imidazoquinolinone, Eur. J. Med. Chem., 45 (2010) 5910–5918. 1544 
[231] S. Van Poecke, H. Munier-Lehmann, O. Helynck, M. Froeyen, S. Van Calenbergh, 1545 
Synthesis and inhibitory activity of thymidine analogues targeting Mycobacterium 1546 
tuberculosis thymidine monophosphate kinase, Bioorganic Med. Chem., 19 (2011) 1547 
7603–7611. 1548 
[232] M. Naik, A. Raichurkar, B.S. Bandodkar, B. V. Varun, S. Bhat, R. Kalkhambkar, K. 1549 
Murugan, R. Menon, J. Bhat, B. Paul, H. Iyer, S. Hussein, J.A. Tucker, M. Vogtherr, 1550 
Author manuscript published in: BBA - General Subjects 
65 
K.J. Embrey, H. McMiken, S. Prasad, A. Gill, B.G. Ugarkar, J. Venkatraman, et al., 1551 
Structure Guided Lead Generation for M tuberculosis Thymidylate Kinase (Mtb 1552 
TMK): Discovery of 3-Cyanopyridone and 1,6-Naphthyridin-2-one as Potent 1553 
Inhibitors, J. Med. Chem., 58 (2015) 753–766. 1554 
[233] H. Cui, J. Carrero-Lérida, A.P.G. Silva, J.L. Whittingham, J.A. Brannigan, L.M. Ruiz-1555 
Pérez, K.D. Read, K.S. Wilson, D. González-Pacanowska, I.H. Gilbert, Synthesis and 1556 
evaluation of α-thymidine analogues as novel antimalarials, J. Med. Chem., 55 (2012) 1557 
10948–10957. 1558 
[234] C. Carnrot, L. Wang, D. Topalis, S. Eriksson, Mechanisms of substrate selectivity for 1559 
Bacillus anthracis thymidylate kinase, Protein Sci., 17 (2008) 1486–1493. 1560 
[235] M.A. Tormo-Más, I. Mir, A. Shrestha, S.M. Tallent, S. Campoy, I. Lasa, J. Barbé, R.P. 1561 
Novick, G.E. Christie, J.R. Penadés, Moonlighting bacteriophage proteins derepress 1562 
staphylococcal pathogenicity islands, Nature, 465 (2010) 779–782. 1563 
[236] J.E. Szabó, V. Németh, V. Papp-Kádár, K. Nyíri, I. Leveles, A.Á. Bendes, I. Zagyva, 1564 
G. Róna, H.L. Pálinkás, B. Besztercei, O. Ozohanics, K. Vékey, K. Liliom, J. Tóth, 1565 
B.G. Vértessy, Highly potent dUTPase inhibition by a bacterial repressor protein 1566 
reveals a novel mechanism for gene expression control, Nucleic Acids Res., 42 (2014) 1567 
11912–20. 1568 
[237] K. Nyíri, B. Kőhegyi, A. Micsonai, J. Kardos, B.G. Vertessy, Evidence-Based 1569 
Structural Model of the Staphylococcal Repressor Protein: Separation of Functions into 1570 
Different Domains, PLoS One, 10 (2015) e0139086. 1571 
[238] K. Nyíri, V. Papp-Kádár, J.E. Szabó, V. Németh, B.G. Vértessy, Exploring the role of 1572 
the phage-specific insert of bacteriophage Φ11 dUTPase, Struct. Chem., 26 (2015) 1573 
1425–1432. 1574 
[239] R. Hirmondó, J.E. Szabó, K. Nyíri, S. Tarjányi, P. Dobrotka, J. Tóth, B.G. Vértessy, 1575 
Cross-species inhibition of dUTPase via the Staphylococcal Stl protein perturbs dNTP 1576 
pool and colony formation in Mycobacterium, DNA Repair (Amst)., 30 (2015) 21–7. 1577 
[240] H.C. Wang, K.C. Hsu, J.M. Yang, M.L. Wu, T.P. Ko, S.R. Lin, A.H.J. Wang, 1578 
Staphylococcus aureus protein SAUGI acts as a uracil-DNA glycosylase inhibitor, 1579 
Nucleic Acids Res., 42 (2014) 1354–1364. 1580 
[241] H.-C. Wang, C.-H. Ho, C.-C. Chou, T.-P. Ko, M.-F. Huang, K.-C. Hsu, A.H.-J. Wang, 1581 
Using structural-based protein engineering to modulate the differential inhibition 1582 
effects of SAUGI on human and HSV uracil DNA glycosylase, Nucleic Acids Res., 1583 
(2016) gkw185. 1584 
 1585 
